Opioids in the hippocampus : [based upon papers and discussion from a workshop review on opioid peptides in the hippocampus which took place on November 10, 1986, at the Society for Neuroscience meeting, in Washington, DC.] by unknown
Opioids
in the
Hippocampus
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration
Opioids in the Hippocampus
Editors:
Jacqueline F. McGinty, Ph.D.
East Carolina University School of Medicine
Greenville, NC
David P. Friedman, Ph.D.
Division of Preclinical Research
National Institute on Drug Abuse
NIDA Research Monograph 82
1988
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Alcohol, Drug Abuse, and Mental Health Administration
National Institute on Drug Abuse
5600 Fishers Lane
Rockville, MD 20857
NIDA Research Monographs are prepared by the research divisions of the
National Institute on Drug Abuse and published by its Office of Science. The
primary objective of the series is to provide critical reviews of research problem
areas and techniques, the content of state-of-the-art conferences, and
integrative research reviews. Its dual publication emphasis IS rapid and targeted
dissemination to the scientific and professional community.
Editorial Advisors
MARTIN W. ADLER, Ph.D.
Temple Universlty School of Medicine
Philadelphia, Pennsylvania
SYDNEY ARCHER, Ph.D.
Rensselaer Polytechnic lnstitute
Troy, New York
RICHARD E. BELLEVILLE, Ph.D.
NB Associates, Health Sciences
RockviIle, Maryland
KARST J. BESTEMAN
Alcohol and Drug Problems Association
of North America
Washington, D. C.
GILBERT J. BOTVIN, Ph.D.
Cornell University Medical College
New York, New York
JOSEPH V BRADY, Ph.D
The Johns Hopkins University School of
Medicine
Baltimore, Maryland
THEODORE J. CICERO, Ph.D.
Washington University School of
Medicine
St Louis, Missouri
MARY L. JACOBSON
National Federation of Parents for
Drug Free Youth
Omaha, Nebraska
REESE T. JONES, M.D.
Langley Porter Neuropsychiatric lnstitute
San Francisco, California
DENISE KANDEL, Ph.D
College of Physicians and Surgeons of
Columbia Universlty
New York, New York
HERBERT KLEBER, M.D.
Yale University School of Medicine
New Haven, Connecticut
RICHARD RUSSO
New Jersey State Department of Health
Trenton, New Jersey
NIDA Research Monograph Series
CHARLES R. SCHUSTER, Ph.D.
Director, NIDA
THEODORE M. PINKERT, M.D., J.D.
Acting Associate Director for Science, NIDA
Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857
Opioids in the Hippocampus
ACKNOWLEDGMENT
This monograph is based upon papers and discussion from a workshop
review on opioid peptides in the hippocampus which took place on
November 10, 1986, at the Society for Neuroscience meeting, in
Washington, DC. The workshop was sponsored by the Office of
Science and the Division of Preclinical Research, National Institute on
Drug Abuse.
COPYRIGHT STATUS
The National Institute on Drug Abuse has obtained permission from
the copyright holders to reproduce certain previously published
figures and tables, as noted in the text. Some of these have been
modified for use in this monograph. Further reproduction of the
copyrighted material is permitted only as part of a reprinting of the
entire publication or chapter. For any other use, the copyright
holder’s permission is required. All other material in this volume
except quoted passages from copyrighted sources is in the public
domain and may be used or reproduced without permission from the
Institute or the authors. Citation of the source is appreciated.
DHHS publication number (ADM)88-1568
Alcohol, Drug Abuse, and Mental Health Administration
Printed 1988
NIDA Research Monographs are indexed in the Index Medicus. They
are selectively included in the coverage of American Statistics Index,
Biosciences Information Service, Chemical Abstracts, Current
Contents, Psychological Abstracts, and Psychopharmacolgy Abstracts.
iv
Preface
The discovery in the middle 1970s of opiate receptors and endoge-
nous opioid peptides was clearly one of the landmark events in the
history of neuroscience. Studies designed to localize and charac-
terize both the receptors and the peptides and to reveal their
functional significance have grown at nearly an exponential rate
since that time. Not surprisingly, a good deal of that effort has
focused on the hippocampal formation. Its relatively simple, lami-
nated, and well-described structure have made it a key model for
studying many aspects of neural processing in the forebrain. Be-
cause different functional components exist almost exclusively in
separate structural compartments, the hippocampus presents an ex-
cellent opportunity to correlate structure with function. As a re-
sult, it was not long after the initial discoveries of brain opioid
systems that effects of oploids on hippocampal electrophysiology
were reported.
The importance of the hippocampus far exceeds its use as a model,
however, because the hippocampus acts as one important gateway
by which sensory information that has been processed by the
neocortex gains access to the limbic system. The hippocampus
therefore plays a key role in memory, even showing the ability to
control its own input and responses based on previous experience.
In addition, the hippocampus appears to be a highly excitable struc-
ture with an unusual vulnerability to seizures. For a variety of
reasons, then, the hippocampus has drawn the attention of
neuroscientists.
Those who wished to understand the role of opioids and their re-
ceptors in neural processing have been among the group studying
the hippocampus, and this monograph summarizes their first decade
of work. As the reports in this volume show, this decade has in-
deed been a profitable one. The neural elements containing opioids
and the particular forms of the peptides they contain are now
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known. The distributions of particular subclasses of opioid recep-
tors have been described on a regional and laminar basis, and the
anatomical relationships of these receptors to the peptides that
presumably bind to them are also known. At the cellular level,
there is a good understanding of how opioids may control the ex-
citability of some kinds of hippocampal neurons, and the receptors
that mediate these effects have in some cases also been described.
Tools have been developed that now allow us to examine within
specific hippocampal pathways the metabolic control of both opioid
peptide content and the genetic message leading to the synthesis of
the propeptides from which hippocampal enkephalins and dynorphins
are derived. In addition, the relations of opioid peptides to other
transmitters and neurally active substances that may be contained
in those pathways are also being described. Even some of the pos-
sible behavioral effects of opioids acting in the hippocampus have
been carefully scrutinized.
This progress, while impressive, serves to highlight what we still
need to learn. Most importantly, the physiological conditions that
lead to the release of opioid peptides from axonal terminations and
the effects elicited under those conditions remain to be revealed.
These questions must be considered the central mysteries about opi-
oids in the hippocampus. In addition, many more specific questions
still need to be answered. For example, although we know the re-
gional and laminar distribution of opioid peptides and their recep-
ton, these do not always coincide. Thus, there are places with
peptide but no receptors and vice versa. The meaning of this mis-
match is still unclear. Moreover, we have not directly demonstrat-
ed the neural elements on which the receptors reside.
Most of the studies of cellular electrophysiology have concentrated
on the pyramidal cells of the CA1 region of the hippocampus. We
need to extend our understanding to other cell types and hippo-
campal regions. CA3 and the dentate gyrus are both coming under
scrutiny, but further efforts are required. The dentate gyrus is
especially crucial because it is the major recipient of the neocorti-
cal input that is relayed through the entorhinal cortex via the
perforant path, and because it is the origin of one of the major
opioid-containing pathways in the hippocampus, the mossy fiber
system.
Our models of metabolic control are still new, and future needs re-
quire that they become even more sophisticated and sensitive so
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that they may reveal the control mechanisms operating under
physiological conditions. Finally, the role of the hippocampus in
the myriad of opioid- and opiate-modulated behavioral effects re-
quires much study, because there is still so much we do not know.
The first 10 years of study of opioids in the hippocampus have pro-
duced a solid base of knowledge and any number of interesting
leads for the future. For the most part, however, the “simple”
questions have been answered. Many of the gaps in our knowledge,
therefore, represent opportunities for the study of difficult prob-
lems. The chapters that follow do an admirable job in explaining
for us the current state of our knowledge and where future chal-
lenges lie.
David P. Friedman, Ph.D.
Division of Preclinical Research
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What We Know and Still Need To
Learn About Opioids in the
Hippocampus
Jacqueline F. McGinty
The study of opioid peptides and their receptors in the hippocampus
integrates two major areas of fascination for neuroscientists. The
current level of interest in hippocampal organization and function-
ing is demonstrated by the presentation of greater than 250 ab-
stracts on the subject at the 1986 Society for Neuroscience
meeting. This number is comparable to the number of abstracts at
this meeting which focused on opiates and opioid peptides. A
significant number of those abstracts represent the most current
work of the participants in the “Opioids in the Hippocampus”
workshop presented at that meeting. This volume summarizes those
presentations, which include data on the anatomical, physiological,
pharmacological, and behavioral aspects of the proenkephalin and
prodynorphin systems in the hippocampal formation (HF, a term
which includes the hippocampus proper and the dentate gyrus; see
below). The authors have integrated the information accumulated
on opioid peptides during the last dozen years with the body of
knowledge accumulated on the neurobiology of the hippocampal
formation during the last century. Together the data point to the
possibility that opioid peptides are intimately involved in the
molecular mechanisms underlying learning and memory and seizure
susceptibility in the hippocampus.
In order to grasp the significance of the distribution of opioid
peptides and receptors in the HF, it is necessary to have a basic
appreciation of hippocampal structure and circuitry. The HF is a
curved structure which must be sectioned in the frontal plane ros-
trally and in the horizontal plane caudally in order to retain the
characteristic “laminar” relationship between the major cellular
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layers throughout the structure. Figure 1 illustrates these relation-
ships in a frontal section through the dorsal HF. The basic route
of information flow through the HF, which is most relevant to the
location of opioid-containing neurons, is via a trisynaptic excitatory
chain. This chain originates in the entorhinal cortex, which pro-
jects highly processed, polymodal sensory information from the en-
tire cerebral cortex through the perforant pathway to the granule
cells in the dentate gyrus of the HF.
FIGURE 1. A schematic illustration of a coronal section through
the dorsal HF of the rat
NOTE: The trisynaptlc excitatory chain consists of the perforant path arising in
the entorhinal cortex, the granule cell-mossy fiber pathway innervating
the CA4-3 cell fieid, and the Schaffer collateral pathway innervating the
CA1 pyramidal cells.
SOURCE: Modified from Henriksen et al. 1982, Copyright 1982, The New York
Academy of Sciences.
The granule cells are the second link in the chain: they project
their axons, the mossy fibers, to the proximal apical dendrites of
the pyramidal cells in the stratum lucidum of the CA3 (inferior)
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region of the HF. The CA3 pyramids (the third link) not only pro-
ject their axons out of the HF but also send a branch (the
Schaffer collateral) to the pyramidal cell dendrites in the stratum
radiatum of the CA1 (superior) region of the HF. In turn, the CA1
pyramids project axons out of the HF primarily through the fornix.
Inhibition mediated by gamma-aminobutyric acid (GABA)- and/or
peptide-containing interneurons (basket cells) whose axons surround
the granule and pyramidal cells is a major control over HF excit-
ability. Without this tonic inhibition, seizures would be free to
march through the uninhibited hippocampus via the trisynaptic
excitatory chain.
In studying the electrophysiological responsiveness of the HF, one
must not assume that the entire structure is homogeneous from the
dorsal through the ventral pole. Recently, it has become clear, for
instance, that the perforant pathway from the entorhinal cortex
into the HF is neurochemically as well as topographically hetero-
geneous, and that the threshold for excitability in the ventral pole
is lower than that in the dorsal pole.
In the early 1980s, proenkephalin- and prodynorphin- (but not pro-
opiomelanocortin-) containing neurons were found in the HF of rats
by immunocytochemistry (Gall et al. 1981; Gall, this volume;
McGinty et al. 1933; McGinty et al. 1994). Three different systems
in the rat HF contain enkephalin immunoreactivity: two of the
three major excitatory pathways, the perforant and mossy fiber
systems (figure 2), and interneurons scattered throughout all layers
of the HF (Gall et al. 1981). Subsequent to Gall’s observations, a
large concentration of prodynorphin peptides was discovered
exclusively in the mossy fiber path which, under normal conditions,
contains less proenkephalin than prodynorphin (Weber et al. 1982;
McGinty et al. 1983; Gall, this volume: Herkenham and McLean, this
volume). More recently, Gall (this volume) has observed some
species differences in the enkephalin distribution in the HF, par-
ticularly a lack of enkephalin immunoreactivity in the perforant
pathway in primates.
The realization that both proenkephalin and prodynorphin are con-
tained in the mossy fiber path raised a number of interesting ques-
tions about opioid peptide interactions in the hippocampus. For
example, are prodynorphin and proenkephalin both expressed in the
same dentate granule cells? We explored this question with double
antibody immunocytochemistry at the light microscopic level in
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FIGURE 2. A schematic illustratio depicting the three major
neuronal types in the trisynaptic chain, the dentate
granule cells, and the CA3 and CA1 pyramidal cells
NOTE: Proenkephalin- containing fibers in the perforant pathyway innervate the
proenkephalin- and prodynorphin-containing dentate granule cells. The
granule cells givee rise to mossy fibers.
SOURCE: Modified from Altman et al. 1973, Copyright 1973, Academic Press.
colchicine-treated rats (McGinty 1985). Colchicine injected directly
into the HF causes granule cell death, but when injected into the
lateral ventricle, it causes axoplasmic transport blockade and can
be used to reveal immunoreactive cell bodies throughout the central
nervous system. In preparations where granule cells were visible,
we were unable to find any granule cells which stained with anti-
sera against products of both prodynorphin (dynorphin B) and
proenkephalin (BAM22P). More recent in situ hybridization histo-
chemical data have demonstrated that most if not all dentate
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granule cells contain prodynorphin messenger RNA (mRNA) (Morris
et al. 1988; Young, unpublished observations), but relatively few
granule cells in a resting or nonstimulated state have been observed
to contain proenkephalin mRNA (Young, unpublished observations).
These results do not rule out the possibility that granule cells are
capable of expressing both prodynorphin and proenkephalin peptides
under certain physiological conditions. In fact, as pointed out by
Gall (this volume) and Hong et al. (this volume), mossy fibers may
be capable of synthesizing and releasing different combinations of
neuroactive substances in response to changes in physiological
activity.
Another question pertaining to the cellular localization of opioid
peptides is whether or not enkephalins or dynorphins in granule
cells and mossy fibers are colocalized with and released with other
synaptically related molecules such as zinc, excitatory amino acids,
or, in some species, cholecystokinin (Gall, this volume). Chavkin et
al. (1983) have demonstrated that opioid peptides are released from
hippocampal slices in a Ca+-dependent manner by K+ depolarization
or by the excitatory amino acid analogue kainic acid. Kainic acid
also releases opioid peptides (Hong et al., this volume) and zinc
(McGinty et al., in press) from mossy fibers in vivo. If other such
substances are released along with opioids when mossy fibers are
activated, investigations of their physiological effects should be
pursued by testing their interactions on pyramidal and granule cell
excitability in addition to examining the effects of each agent
alone. Chavkin et al. (this volume) and Segal (this volume)
introduce their most recent experiments in which the actions of
enkephalins in the hippocampus are blocked with an excitatory
amino acid antagonist (see below).
Two electrophysiological observations in rats initially attracted
attention to the nature of opiate actions in the hippocampus
(reviewed by Henriksen et al. (this volume) and Chavkin et al. (this
volume)). First, intracerebroventricular (ICV) infusions of beta-
endorphin or met5-enkephalin into unanesthetized rats were found
to induce electroencephalographic seizure activity in the hippo-
campus and amygdala in the absence of frank motor convulsions
(Urca et al. 1977; Henriksen et al. 1978). These “limbic seizures”
were accompanied by a frozen posture interrupted by “wet dog
shakes,” a behavior which also occurs during opiate withdrawal in
rodents. According to Hong et al. (this volume), the occurrence of
wet dog shakes appears to depend on the actions of enkephalin on
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or in the granule cell-mossy fiber pathway. Second, Nicoll and
colleagues (1977) demonstrated a unique excitatory effect of
electrophoresed enkephalin on individual hippocampal pyramidal
cells. Only inhibitory actions had been recorded in other regions
of the mammalian brain (Nicoll et al. 1977). Intracellular record-
ings (Zieglgänsberger et al. 1979), however, were unable to demon-
strate the changes in pyramidal cell membrane polarization which
should have occurred if opiate receptors on pyramidal cells were
mediating the excitation. Zieglgänsberger and colleagues reconciled
these two apparently discrepant findings by hypothesizing that
inhibitory GABA-containing neurons intervened between inhibitory
enkephalin-containing neurons and hippocampal pyramidal cells. In
this scenario, when enkephalin is released, it would cause inhibition
of GABA release and a resulting disinhibition of pyramidal cells.
Recently it has been learned that enkephalin analogues do decrease
the firing rates (Lee et al. 1980) of and hyperpolarize the mem-
branes of CA1 intemeurons by increasing potassium conductance
(Nicoll and Madison 1984). The study of the effects of opioid pep-
tides in the dentate gyrus has a much shorter history; progress in
this area is reported by Henriksen et al. (this volume) and Chavkin
et al. (this volume).
To date, the enkephalin-GABA-pyramidal cell circuitry proposed by
electrophysiologists in CA1 has neither been demonstrated nor
refuted by morphological data. A demonstration of monosynaptic
connections between enkephalin- and GABA-containing cells would
require immunostaining for GABA (or glutamic acid decarboxylase,
which synthesizes GABA from glutamate) and enkephalin simultane-
ously at the electron microscopic level. There is not yet, however,
even a published account of enkephalin immunoreactivity alone in
the hippocampus at the ultrastructural level. In other sytems
(teleost and avian retina), it has been shown that exogenously
applied enkephalins inhibit the K+-evoked release of GABA from
amacrine cells and that enkephalin is localized in some amacrine
cells which take up [3H]GABA (Chin and Lam 1982).
Until the localization of enkephalin and GABA at the ultrastructural
level is performed together successfully, we will not know what
class of hippocampal neurons have oploid receptors on their plasma
membranes, and, as a result, we will not know by what mechanism
enkephalin excites pyramidal cells. Although receptor auto-
radiography has provided us with detailed maps of the distributions
of the mu, delta, and kappa opioid receptor subtypes within the
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different fields and layers of the HF (Herkenham and McLean, this
volume), the resolution of these receptor maps does not yet allow
us to discern on what cell types the receptors are located. We
still do not know if GABA-containing cells and/or pyramidal cells
possess opioid receptors. What we do know is that the pyramidal
cell layer, which is only sparsely innervated by opioidergic termi-
nals in many species, contains the densest concentration of opioid
receptor subtypes: whereas the mossy fiber layer, which contains
the densest concentration of opioidergic terminals, has few, if any,
opiate receptors. In other species, the distribution of opioid-
peptide-containing terminals remains constant, but the distribution
of opioid receptors is different. Herkenham and McLean (this
volume) discuss the implications of this receptor-peptide
“mismatching” in several species and provide some indication of
which receptor subtypes may be in a position to mediate opioid
peptide actions in different hippocampal regions.
The actions of hippocampal dynorphins on opioid receptor sub
populations are also the subject of vigorous investigation. In
contrast to the seizurogenic effects of met5-enkephalin and beta-
endorphin after ICV infusion, and their excitatory effects on single
pyramidal cells, dynorphins not only do not produce seizures
(Henriksen et al. 1982), but they also appear to have naloxons
reversible excitatory as well as non-naloxone-reversible inhibitory
actions at the single-cell level (Henriksen et al. 1982; Gruol et al.
1983; Moises and Walker 1985). Dynorphin effects, however, are
mixed or are not very potent on pyramidal cells in the CA3 region
of the hippocampus, which contains the most dynorphin-immuno-
stained terminals. The paper by Chavkin et al. (this volume) ex-
plores the current status of this paradox by addressing what oploid
receptor subtype(s) are activated by dynorphins in various regions
of the hippocampus. Chavkin and colleagues replace the earlier
hope that each class of opioid peptide would act via one class of
opioid receptor with evidence that each peptide probably acts to
different degrees on whatever receptor subtype(s) are present.
The presence of opioid peptides in excitatory pathways of the HF
has led to explorations of the alterations in the metabolism of
endogenous opioid peptides in response to hippocampal hyper-
excitation. Hong et al. (1979) first demonstrated that kainic acid
administration caused a seizure-linked depletion followed by a
robust increase in met5-enkephalin levels in the hippocampus.
Since then, Hong’s group, in collaboration with my own, has shown
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that recovery of mossy fiber and perforant path proenkephalin and
prodynorphin peptide and mRNA levels in response to seizures
elicited by kainic acid, electroconvulsive shock, or kindling occur
with very different time courses. These data complement the
findings of Gall (this volume), who has shown that a lesion of the
dentate hilus in mice also causes seizures that release opioids and
cholecystokinin from the mossy fibers. In all of these seizure
models, each peptide has a different rate of return to normal levels
in the postictal period. Taken together, these studies indicate
differential regulation of opioid peptide gene expression in hippo-
campal pathways and differential control of release of opioid
peptides from the axons comprising these pathways. They have
provided us with models in which to study the physiological conse-
quences of short- and long-term alterations in peptide content and
metabolism in the HF and hold promise for uncovering the role(s)
of opioid peptides in hippocampal excitability.
Finally, in what way can the actions of hippocampal opioid peptides
be associated with the role of the hippocampus in overall brain
function? Chavkin et al. (this volume) and Segal (this volume)
report their most recent data on the mediation of a specific com-
ponent of opioid excitation of pyramidal cells in CA1 by receptors
for the excitatory amino acid N-methyl-D-aspartate (NMDA).
Activation of NMDA receptors occurs in long-term potentiation, the
putative substrate for hippocampal learning and memory processing.
Indeed, Segal (this volume) describes exciting new data showing
that mu opioid receptor activation enables the expression of long-
term excitatory postsynapatic potentials evoked by associating
afferent stimulation with depolarization of CA1 pyramidal cells, an
illustration of a so-called Hebbian synapse. Thus, by enhancing the
activity of excitatory neurotransmitters, possibly by decreasing
GABA-mediated inhibitory tone at specific synapses, opioid peptides
may be essential to the very fabric of hippocampal synaptic plas-
ticity in which memory is stored through changes in the efficacy of
transmission among elements.
Based solely on the fact that opioid peptides are generously rep
resented in important hippocampal circuits, one would anticipate
that they would play a significant role in hippocampal-associated
behaviors. Gallagher (this volume) reviews the evidence that exog-
enous opioid agonists diminish, and opioid antagonists improve,
behavioral performance on memory tasks known to be dependent on
integrity of the HF. However, it is not clear from these data that
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opioid peptidergic circuits in the hippocampus are involved in these
behaviors or that the tasks described lead to the release of endog-
enous opioids. A stronger indication that endogenous hlppocampal
opioids are involved in spatial learning is provided by the data of
Collier and Routtenberg (1984), showing that naloxone can block
the forgetting of a learned spatial task, the disruption of which
was induced by Stimulation of the dentate gyrus, presumably leading
to the release of opioid peptides. Gallagher also presents a line of
reasoning based on data from her laboratory indicating that choli-
nergic afferents from the septal nuclei to the hippocampus, which
are important for the acquisition and retention of spatial tasks, are
under opioid control. Finally, preliminary data from Gallagher’s
laboratory are presented which positively correlate changes in
hippocampal opioid peptide levels with the acquisition and perform-
ance of a spatial task in a radial arm maze.
The authors contributing to this monograph hope that they were
successful in synthesizing in a thoughtful and useful way the most
current multidisciplinary data on the cellular localization and
actions of opioid peptides in the HF. In addition, we hope we have
achieved our goal of highlighting the most exciting and fruitful
areas for future research, which will address not only the role of
opioid peptides in the hippocampus but in the overall scheme of
brain functioning as well.
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Localization and Seizure-Induced
Alterations of Opioid Peptides and
CCK in the Hippocampus
Christine M. Gall
INTRODUCTION
As a consequence of its very simple laminated anatomy, the hippo-
campal formation has come to occupy a central position in neuro-
science research as a model system for the analysis of cellular
operations in the forebrain. As discussed in the various contri-
butions to this volume, this has included use of the hippocampus as
a vehicle for analyses of the role of opioid peptides in neuronal
processing and behavior. Evaluation of the function of specific
neuropeptides in the hippocampus, as elsewhere, must begin with
consideration of such fundamental issues as their distribution, the
extent to which this distribution is consistent across species, and
the ontogeny of the peptides in the context of the morphological
and physiological development of the structure. Optimally, one
would also like to identify physiological processes which influence,
and/or are lnfluenced by, the peptides under investigation. In the
following pages, I will discuss the above points with regard to en-
kephalin, dynorphln, and cholecystokinin (CCK) in the hippocampus.
LOCALIZATlON Of OPIOID PEPTIDES IN THE HlPPOCAMPUS
As described in my original report (Gail et al. 1981 b) and verified
by subsequent immunocytochemical and biochemical studies,
enkephalin immunoreactivity is localized within three distinct axonal
systems in the rat hippocampal formation: the mossy fiber axons
of the dentate gyrus granule cells which innervate pyramidal cells
of region CA3; a thin band of axons distributed along the border of
the stratum radiatum and the stratum lacunosum-moleculare of
region CA1; and perforant path axons which arise from the lateral
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entorhinal/perirhinal cortices, distribute within the Stratum
iacunosum-moleculare, and innervate the distal third of the dentate
gyrus molecular layer. The latter system is most dense in the
temporal hippocampus. Enkephalin immunoreactivity is also
observed within sparsely distributed perikarya throughout the
hippocampus proper and (in untreated rats) within only a small
number of morphologically characteristic dentate gyrus granule
ceils. Dynorphin exhibits a much more restricted distribution in
the rat hippocampus, being localized within the mossy fiber axonal
system (McGinty et al. 1983) and very few scattered, multipolar
neurons. Initially, the reported codistribution of [leu5]enkephalin
and dynorphin immunoreactivities within the mossy fiber system
aroused concern that some of the enkephalin immunostaining may
have been attributable to cross-reactivity of the enkephalin antisera
with dynorphin (McGinty et al. 1993). However, subsequent studies
have demonstrated that the dentate gyrus granule cells synthesize,
and the mossy fiber axons contain, methionine enkephalin as well
as the proenkephalin A fragments methionine-enkephalin-ArgPhe,
methionine-enkephaiin-ArgGlyLeu, BAM 18, and BAM 22 (McGinty et
al. 1984; White et al. 1987).
The localization of enkephalin and dynorphin within the mossy fiber
system is invariably conserved across all species thus far examined,
including rat, mouse, hamster, vole, European hedgehog, gerbil,
guinea pig, cat, tree shrew, and Old World monkey (Gall et al.
1981b; Fitzpatrick and Johnson 1981; Tielen et al. 1982; Stengaard-
Pedersen et al. 1983; Gall and Lauterborn, unpublished observa-
tions). ln contrast, subtle interspecies differences are evident in
the distribution of enkephalin within strata lacunosum and molecu-
lare of the hippocampus proper, and these seem associated with the
more striking differences in the localization of enkephalin within
the perforant path afferents to the dentate gyrus. For example, in
stratum lacunosum-moleculare of the rat ventral hippocampus,
terminal-like immunoreactive puncta are most densely distributed
within a zone extending from the subiculum into the adjacent
region of CA1, and within region CA3 in a field continuous with
the dentate gyrus outer molecular layer (OML) (figures 1 and 2).
ln contrast, there is very little immunostaining in the hamster
stratum lacunosum-moleculare of CA3, but there is a rather dense
patch of immunoreactive puncta within this lamina at the CA2 limit
of region CA1. In the hamster, there is also very little immuno-
reactivity within the dentate gyrus OML in the guinea pig,
enkephalin immunoreactivity is only prominent in the extreme
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temporal tip of the CA3 stratum moleculare and in the dentate
gyrus OML (Tielen et al. 1982), while in the hedgehog (Stengaard-
Pedersen et al. 1983) and the tree shrew (Fitzpatrick and Johnson
1981), enkephalin immunoreactivity has not been observed in either
of these laminae.
FIGURE 1. Illustrations of the distribution of enkephalin-like and
dynorphin-like immunoreactivity
NOTE: Enkephalln (ENK)-like (drawing and left micrograph) and dynorphin
(DYN)-like immunoreactivity (tight micrograph) in a horizontal section
through the ventral rat hippocampus (peroxidase antiperoxidase tech-
nique). Abbreviations: sl-m, stratum lacunosum-moleculare; sg, stratum
granulosum: mf, mossy fibers; oml, outer molecular layer: sp, stratum
pyramidale.
In the Old World monkey Macaca fascicularis, enkephalin-immuno-
reactive mossy fibers are present within the stratum lucidum, but
there is no clear lamination of enkephalin-positive elements in the
molecular layers of the hippocampus proper. Only a few scattered
immunoreactive axons and terminal puncta are seen within the stra-
tum radiatum and, with somewhat greater density, within the stra-
tum moleculare. Similarly, in the dentate gyrus molecular layer,
enkephalin is localized within a few broadly distributed varicose
axons: no prominent or laminated immunoreactive afferent systems
are seen (figure 2).
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FIGURE 2. Differences in the distribution of enkephalin immuno-
reactivity in the ventral dentate gyrus of the rat, the
monkey, and the cat
NOTE: Light-field (A and C) and dark-field (D and E) photomicrogmphs illus-
trating differences in the distribution of enkephalin immunoreactivity in
the ventral dentate gyrus of the rat (A), the monkey (B), and the cat
(C), and the localization of fine punctate immunoreactivity overlying the
stratum pyramidale (sp) of the cat hippocampal region CA1. In A, B,
and C, the arrowheads bracket the dentate gyrus molecular layer which
can be seen to contain one distal outer molecular layer band of immuno-
reactivity in the rat (A), two bands of immunoreactivity in the cat (C),
and no Laminated immunoreactive systems in the monkey. The mossy A
ber system, in the hilus below the stratum granulosum (sg), is clearly
immunoreactive in all three animals (A, B. and C). Abbreviations: a.
alveus; F. hippocampal fissure: so, stratum oriens: sr, stratum radiatum.
In contrast to all other animals studied, the cat has two distinct
and dense bands of enkephalin immunoreactivity occupying the mid-
dle and outer thirds of the dentate gyrus molecular layer across its
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full septotemporal extent (figure 2). The molecular layer is con-
sidered to be composed of three laminae defined by the laminated
termination of afferent systems: the inner, middle, and outer
molecular layers receive hippocampal commissural/associational,
medial entorhinal, and lateral entorhinal afferents, respectively. As
such it seems that, in the cat, afferents from both the medial and
lateral entorhinal cortex have relatively high enkephalin content.
In regard to the distibution of opioid receptors in the hippocampus
(Herkenham and McLean, this volume), it is noteworthy that neither
enkephalin nor dynorphin immunoreactivtty is localized to a signifi-
cant number of axons or cells within the stratum pyramidale of the
hippocampus proper in most animals. The only known exception to
this generality is, again, the cat. In region CA1 of the cat hippo-
campus, fine enkephalin-immunoreactive terminal-like puncta are
distributed quite precisely over the stratum pyramidale and the
adjacent portion of the stratum oriens in a manner reminiscent of
the distribution of opioid ligand binding observed in other species
(figure 2).
DISTRIBUTION OF CCK IN THE HIPPOCAMPUS
Significantly more interspecies variability has been noted in the
hippocampal distribution of a third, nonopioid peptide, cholecysto-
kinin octapeptide (CCK). CCK is of interest when considering
hippocampal opioids in that this peptide is codistrlbuted with en-
kephalin and dynorphin in the mossy fiber system of some species,
is reportedly antagonistic to opioid-mediated processes in other
systems (Fads et al. 1983), and is influenced by the same physio-
logical events which after hippocampal opioid synthesis (vide infra).
CCK is reliably localized within scattered perikarya throughout the
hippocampus proper and the dentate gyrus hilus, and within coarse
pericellular axons in the stratum pyramidale. There are species
differences in the density and distribution of CCK in the commis-
sural/associational afferents to the dentate gyrus inner molecular
layer, and the medial perforant path afferents to the dentate gyrus
middle molecular layer (Stengaard-Pedersen et al. 1983; Gall 1984a;
Gall et al. 1988). More pertinent here, CCK immunoreactivity has
been localized within dentate gyrus granule cells and the axons of
the mossy fiber system of guinea pig, European hedgehog
(Stengaard-Pedersen et al. 1983; Gall 1984a), mouse (Gall et al.
1986), and M. fascicularis (Gall and Lauterborn, unpublished), but is
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absent from this system in rat (Greenwood et al. 1981), gerbil,
rabbit, and cat (Gall, unpublished).
The extent to which the three mossy fiber peptides are colocalized
within individual mossy fiber terminal boutons, as opposed to being
localized within separate elements within this system, is not as yet
known. In a double-labelling study, McGinty (1985) found immuno-
reactivity for dynorphin B and the proenkephalin A product BAM 22
in separate granule cells in colchicine-treated rats. However,
enkephalin synthesis and concentration In the dentate gyrus granule
cells has been demonstrated to be exquisitely sensitive to recent
physiological activity. In the normal state, without physiological
stimulation of synthesis, only a fraction of the granule cells which
are able to synthesize enkephalin contain detectable immuno-
reactivity (see below). Consequently, the absence of dynorphin/
enkephalin colocalizatlon In the normal rat, or enkephalin/CCK
colocalization in the normal mouse, does not necessarily mean that
these peptides arise from biochemically distinct perikarya. lt is
possible that individual cells do not synthesize these peptides in
detectable quantities all the time or at the same time. There is, in
fact, evidence that the synthesis of mossy fiber peptides is in-
dependently, or possibly even reciprocally, regulated in ontogeny
and adulthood, as will be discussed next.
ONTOGENY OF ENKEPHALIN, DYNORPHIN, AND CCK IMMUNO-
REACTlVITY IN THE HIPPOCAMPUS
Data on the ontogeny of opioid peptide immunoreactivity in the
hippocampus, and most particularly within the hippocampal mossy
fiber system, is directly relevant to the possible functions of the
opioids in hippocampal physiology. In young rats, enkephalin
immunoreactivity within the lateral perforant path afferents to the
ventral dentate outer molecular layer is evident at the time of
afferent ingrowth—4 days postnatal (dpn). In contrast, enkephalin
is not detectable within the mossy fibers until about 12 dpn and, in
both the rat and the mouse, is first seen in a few large, well-
elaborated mossy fiber boutons (Gall 1984b; Gall et al. 1984). The
mossy fibers are known to grow into the stratum lucidum of region
CA3 by 3 dpn (Zimmer and Haug 1978), to have formed morphologi-
cally recognizable and functionally competent synapses by 5 dpn
(Bliss et al. 1974; Sterling and Bliss 1978), and, only after synaptic
contacts have been established, to slowly elaborate the large termi-
nal boutons characteristic of the adult (Amaral and Dent 1981).
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FIGURE 3. The hilus lesion and seizure-induced changes in mossy
fiber enkephalin immunoreactivity
NOTE: Photomicrographs illustrating (A) the extent of the electrolytic hilus
lesion found to initiate recurrent limbic seizuree activity (Nissl stain,
coronal section from rat), and (Band C) the increase in enkaphalin
lnmunostaining in the mossy fiber system (region CA3b) 4 days after a
contralateral hilus lesion (C), relative to that seen in a paired, untreated
rat (B). Abbreviations: h, hilus; mf, mossy fibers: sg, stratum granu-
losum: sl, stratum lucidum: sp, stratum pyramidale.
Considered in this context, it is clear that enkephalin is first
detectable within the mossy fibers fairly late in the morphological
development of the system and well after the establishment of
synaptic transmission.
Dynorphin and, in the mouse, CCK both appear earlier in the
development of the mossy fiber system, and closer to the apparent
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onset of synaptic function. In the rat and the mouse, both pep-
tides are first detectable on 6 dpn in small, indistinct puncta
within the dentate gyrus hilus and the stratum lucidum (Gall 1984b).
The immunoreactive elements within the stratum lucidum enlarge
with age, and it is only at later time points (12 to 14 dpn) that
both immunoreactivities are clearly localized within the large,
irregularly shaped terminal boutons characteristic of the mossy
fibers in the adult. Thus, in contrast to the development of en-
kephalin within this system, both dynorphin and CCK emerge very
soon in the wake of synaptogenesis, suggesting that these peptides,
but not enkephalin, may be present and active from the onset of
synaptic transmission at the mossy fiber synapse.
EVIDENCE FOR THE REGULATlON OF HIPPOCAMPAL NEURO-
PEPTlDE LEVELS BY PHYSIOLOGICAL ACTIVITY
Evidence that opioid peptide levels in the hippocampus and else-
where are regulated to a significant extent by physiological activity
is shown in studies of the effects of experimentally induced sei-
zures. Hong and coworkers first demonstrated that, following re-
current seizures induced by either repeated electroconvulsive shock
(Hong et al. 1979) or intracerebroventricular (ICV) injection of
kainic acid (Hong et al. 1980), the level of enkephalin immuno-
reactivity in the hippocampus increases threefold as measured by
radioimmunoassay (RIA) (Hong, this volume). These data provide an
interpretation for the observation I had made that a small electro-
lytic lesion placed in the dentate gyrus hilus induced a large bi-
lateral increase in mossy fiber enkephalin immunoreactivity (Gall et
al. 1981 b). Since that time, a number of other seizure-producing
treatments have been demonstrated to alter both enkephalin and
dynorphin levels in the hippocampus. Work in my laboratory has
focused on the effect of limbic seizures induced by either focal
lesion placement in the dentate gyrus hilus or, for the purpose of
comparison, ICV injection of kainic acid, on enkephalin, dynorphin,
and CCK systems in rat and mouse hippocampi. Both treatments
induce dramatic increases in enkephalin immunoreactivity in the
hippocampus which are most prominently localized within the
hippocampal mossy fiber system (Gall et al. 1981a). Although
enkephalin immunoreactivity is clearly altered in other brain areas
following these treatments, our work has centered on peptide
changes in the mossy fibers due to the codistribution of three dis-
tinct peptide families within this one axonal system; the relatively
high sensitivity of mossy fiber peptide levels to seizure activity;
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and the anatomical suitability of this compact, well-characterized,
and strictly unilateral axonal system to both biochemical and
immunocytochemical analysis.
In the rat, placement of a small unilateral electrolytic lesion in the
hilus of the dentate gyrus (figure 3) induces synchronous, bilateral
epiieptiform activity in the hippocampus, which is first observed 1
to 2 hours postlesion and continues, with periodic full paroxysmal
discharges, for approximately 10 hours thereafter. Throughout this
period, the animals exhibit intermittent convulsive behavioral sei-
zures reminiscent of those described to accompany kindled limbic
seizures by Racine (1972). As such, three to seven episodes of
stage 4 or 5 convulsive seizure (rearing with facial and forelimb
clonus, rearing and falling), and more numerous displays of associ-
ated subconvulsive seizure behavior (forelimb clonus and wet dog
shakes) are typically observed. This lesion directly severs a narrow
rostrocaudal span of the strictly ipsilateral, and highly topographic,
mossy fiber system within the lesioned hippocampus; the majority of
the mossy fibers within the ipsilateral hippocampus and all of the
mossy fibers within the contralateral hippocampus remain fully in-
tact. Kaink acid induces more continuous seizure activity lasting 3
to 6 hours after an ICV injection, does not induce mossy fiber
degeneration, but does result in the death of neurons within region
CA3 of the rostral, ipsilateral hippocampus.
Enkephalin levels undergo a biphasic fluctuation following seizures
induced by either treatment (Pico et al. 1985; Gall et al., in press:
Kanamatsu et al. 1986b). In rats sacrificed 6 to 12 hours following
a hilus lesion, enkephalin immunostaining is completely depleted
from the mossy fiber system bilaterally. By 18 to 20 hours,
immunoreactivity has returned to near-normal levels, and by 24
hours, immunostaining is clearly greater than that observed in
paired controls. Enkephalin immunoreactivity in the mossy fibers
continues to increase until it reaches an apparent maximum at 3 to
5 days postlesion, and thereafter decreases to normal by about
postlesion day 10. At its maximal elevation, hippocampal enkephalin
content reaches over fourfold above normal as measured by RIA.
The time course for the fluctuations in hippocampal enkephalin
content induced by the hilus lesion is comparable to that observed
following ICV or intrastriatal injection of kalnic acid in our
immunocytochemical material and in the reports of Hong et al.
(1980) and Kanamatsu et al. (1988b). We find enkephalin levels are
also transiently elevated in other areas following either the hilus
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FIGURE 4. Seizure-induced changes in mossy fiber enkephalin,
dynorphin, and CCK immunoreactivities in mouse
hippocampus
NOTE: Photomicrographs of coronal sections through the mouse hippocampus
illustrating the distribution and density of peroxidase antiperoxidase
immunostaining for enkephalin (A and B), dynorphin (C and D), and
CCK (E and F) in untreated control mice (A, C, and E) and paired mice
sacrificed 4 days after the contralateral placement of a seizure-
producing hilus lesion (B, D, and E). Abbreviations: iml, inner molecu-
lar layer; sg, stratum granulosum; sp, stratum pyramidale. Arrows
indicate mossy fiber system.
lesion or kainic acid, including the temporoammonic/lateral perfo-
rant path, entorhinal cortex, lateral septum, and amygdala.
The effect of hilus-lesion-induced seizure activity on the regulation
of mossy fiber enkephalin content is somewhat selective in that
neither dynorphin nor CCK immunoreactivities are increased by this
treatment. As mentioned above, dynorphin and, in the mouse, CCK
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immunoreactivities are codistributed with enkephalin in the mossy
fiber axonal system. Twelve hours after the placement of a uni-
lateral hilus lesion in rats or mice, immunostaining for both dynor-
phin A- and dynorphin B-like immunoreactivity is greatly reduced
in the mossy fiber system bilaterally. At 2 and 4 days postlesion,
dynorphin levels remain below normal, but the decreases seen at
these time points are not large and are highly variable: in some
animals with elevated mossy fiber enkephalin content, dynorphin
immunostaining was not clearly lower than that seen in paired con-
trols. Dynorphin immunoreactivity was never observed to be ele-
vated in the mossy fibers at these or longer intervals following
hilus lesion placement.
In contrast to the effect of hilus-lesion-induced seizure activity on
enkephalin and dynorphin, this treatment caused a complete and
prolonged bilateral depletion of CCK which was restricted to the
mossy fiber system. As mentioned above, in the mouse hippo-
campus, CCK is localized within the commissural/associational
afferents to the dentate inner molecular layer, within local circuit
neurons and their axonal arbors in the stratum pyramidale, as well
as within the mossy fibers. Six hours after hilus lesion placement
in the mouse, CCK is depleted from the mossy fibers bilaterally,
while immunostaining appears normal in other areas of the hippo-
campus. At 4 days postlesion (the time of maximal enkephalin
elevation), the pattern of CCK immunoreactivity remains unchanged:
no immunoreactivity is apparent within the mossy fiber system,
while other CCK systems stain normally. Low doses of kainic acid
(0.05 to 0.1 µg, ICV) induce precisely the same alterations in
mouse mossy fiber peptide immunoreactivity as those seen following
the hilus lesion: an initial depletion of immunostaining for all
three peptides; a return and supranormal elevation of enkephalin
immunoreactivity which appears maximal 3 to 5 days posttreatment;
a persistent depletion of CCK restricted to the mossy fibers; and a
partial reduction in immunostaining for dynorphin (Gall 1984c).
Data on the duration of altered peptide immunoreactivity in the
mouse following either the hilus lesion or kainic acid treatment
serve to further dissociate the effects of seizures on mossy fiber
enkephalin and CCK, and to indicate that aberrant peptide levels
induced by seizures can become permanent. Unlike the rat, the
duration of elevated mossy fiber enkephalin in the mouse is highly
variable: while enkephalin immunostaining has returned to normal
in most animals sacrificed 2 weeks posttreatment, in four mice
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which initially exhibited particularly severe seizure behavior,
enkephalin immunostaining was still dramatically elevated in the
mossy fibers after 2 to 6 months’ survival. The absence of CCK
from the mossy fibers generally outlasted the enkephalin elevation.
In a number of the experimental mice with normal enkephalin
immunostaining 14 to 20 days posttreatment, CCK immunoreactivii
had not yet returned to the mossy fiber system. Among the mice
allowed 2 to 6 months’ survival, all mice with normal enkephalin
immunoreactivity also exhibited normal CCK immunoreactivity in the
mossy fibers. Those few animals with a persistent elevation in
mossy fiber enkephalin exhibited absolutely no immunostaining for
CCK in this system (Gall et al. 1986).
Because enkephalin, dynorphin, and CCK are similarly depleted from
the mossy fiber system during the recurrent seizure episode, one
might argue that the dentate gyrus granule cells, which synthesize
and release these peptides, are similarly stimulated by the epi-
leptiform event. However, the postictal levels of the three mossy
fiber peptides are altered in distinctly different fashions. Either
the physiological activity or peptide depletion clearly stimulates a
large increase in enkephalin content. The same processes lead to
an equally dramatic, and somewhat more persistent, loss of mossy
fiber CCK. Dynorphin levels are less severely affected, seeming
only partially depressed in most experimental animals.
ALTERATIONS IN ENKEPHALIN SYNTHESIS FOLLOWING SEIZURE
There is now substantial evidence that the increase in enkephalin
content observed in the hippocampus and elsewhere (Yoshikawa et
al. 1985) following recurrent seizures is due to increased synthesis.
Work done in my laboratory in collaboration with Drs. Jeff White
and Jeff McKelvy (of State University of New York at Stony
Brook) has specifically examined the effect of recurrent seizure
activity induced by unilateral hilus lesion on enkephalin metabolism
in the dentate gyrus granule cells which give rise to the mossy
fiber axonal system. As reviewed earlier, following hilus lesion
placement in the rat, enkephalin immunoreactivity increased within
the mossy fiber axons bilaterally from 12 hours to 3 days post-
lesion. In order to determine the effect of this treatment on
enkephalin synthesis within the hippocampus contralateral to the
lesion, we injected 35S-methionine by osmotic minipump into the
dentate gyrus during the interval from 24 to 28 hours postlesion.
The incorporation of the isotope into chromatographically identified
23
methionine-enkephalin, methionine-enkephalin-ArgPhe, methionine-
enkephalin-ArgGlyLeu, and BAM 18 purified from region CA3 was
measured at 30 hours postlesion. We found that there was a 14-
fold greater incorporation of the radiolabel into methionine-
enkephalin in the mossy fiber system of hilus-lesioned rats relative
to paired controls, while there was no change in the ratio of the
four proenkephalin A peptides (White et al. 1987). This indicates
that hilus-lesion-induced seizure activity causes a large increase in
proenkephalin A synthesis without a fundamental change in post-
translational processing.
In a separate series of rats, we conducted Northern blot analysis to
determine the effect of hilus-lesion-induced seizure activity on
preproenkephalin messenger RNA (mRNA) content in the dentate
gyrus contralateral to lesion placement (figure 5). We detected an
increase in the single species of RNA hybridizing to our 32P-
labelled RNA probe as early as 3 hours posttesion, less than 2
hours after the onset of seizure activity. Preproenkephalin mRNA
levels reached a maximal increase of about 24-fold above normal at
30 hours postlesion. By 4 days, message levels were only slightly
higher than those observed in untreated rats, and by 10 days the
experimental and control values were equivalent (White et al. 1987;
White and Gall 1987). As expected if these increases in enkephalin
message were induced by seizure activity rather than some other
aspect of treatment, we found that maintenance of animals under
anesthesia with the anticonvulsants sodium pentobarbital and phe-
nytoin from lesion until sacrifice did, in fact, significantly block
the hilus lesion induction of increased preproenkephalin mRNA in
the dentate gyrus (figure 5).
The observation that recurrent seizure activity induces increased
enkephalin immunoreactivity and synthesis is consistent with the
results of other laboratories using different experimental manipu-
lations including kainic acid injection (Kanamatsu et al. 1986b),
repeated electroconvulsive shock (ECS) (Kanamatsu et al. 1986a),
and chemical (pentylenetetrazol)- and amygdala-stimulation-induced
kindling (Vindrola et al. 1984; ladarola et al. 1986). Together,
these treatments have elicited enkephalin increases in the hippo-
campus, entorhinal cortex, amygdala, ventral pallidum, septum,
hypothalamus, and substantia nigra, although there are differences
in the reported distribution and magnitude of increased enkephalin
immunoreactivity with different modes of seizure induction. Fol-
lowing either the hilus lesion or kainic acid, the greatest increase
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FIGURE 5. Bar graph illustrating the time course of increased
preproenkephalin A mRNA in the rat dentate gyrus
contralateral to a hilus lesion
NOTE: Each bar represents the mean densitometric value from autoradiograms of
Northern blots for at least three animals at each time point. Cross-
hatched bars indicate rats anesthetized during surgery with ketamlne/
xylazlne; black bar indicates rats maintained under pentobarbital/
phenytoin anesthesia from lesion until sacrifice.
in enkephalin immunoreactivity is localized in the mossy fiber sys-
tem. In contrast, following ECS, elevated hippocampal enkephalin
levels are greatest in the perforant path afferents from the ento-
rhinal cortex. ECS induces the largest increases in enkephalin
content in the hypothalamus, whereas enkephalin levels are un-
affected in this area following kainic acid. lt is noteworthy that
all effective paradigms include recurrent seizure activity:
Kanamatsu et al. (1986a) did not observe significantly increased
hippocampal enkephalin content following less than six consecutive
ECS treatments. In both the hilus lesion (White and Gall 1987) and
kainic acid (Kanamatsu et al. 1986b) paradigms, increased synthesis,
as indicated by increased preproenkephalin mRNA levels, begins
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early in the period of recurrent seizure activity and, in the hilus
lesion model, continues to increase for several hours after the
termination of behavioral seizures.
The effect of seizures on both dynorphin and CCK is significantly
less consistent across paradigms. While repeated ECS leads to in-
creased dynorphin immunoreactivity in the substantia nigra, medial
basal hypothalamus, and ventral pallidum (Kanamatsu 1986a), ECS,
the hilus lesion, low doses of ICV kainic acid (present data), and
stage 5 amygdaloid kindling (ladarola et al. 1986) effect a reduction
in dynorphin in the mossy fibers lasting several days at least.
High doses of kainic acid injected into the striatum reportedly
induce a rapidly transient increase in mossy fiber dynorphin
(Kanamatsu et al. 1986b). While both amygdaloid kindling (ladarola
et al. 1986) and kainic acid (Meyer et al. 1986) have been reported
to increase CCK immunoreactivity in the substantia nigra and
hippocampus of rats, we have found that both the hilus lesion and
kainic acid eliminate CCK from the mouse mossy fiber system.
These results are not directly contradictory, however, in that CCK
immunoreactivity is not localized within the mossy fibers of the
rat.
CONCLUDING COMMENTS
lt is now clear that two separate opioid peptide families, represent-
ed by enkephalin and dynorphin, are localized and, to a large ex-
tent, codistributed within the hippocampal formation. While both
peptides are consistently observed within the dentate gyrus granule
cells and their mossy fiber axons in a number of different mam-
mals, there are substantial interspecies differences in the localiza-
tion of enkephalin within the entorhinal afferents to the dentate
gyrus and hippocampus proper.
Data on the ontogeny of and the effect of seizures on enkephalin,
dynorphin, and CCK in the mossy fiber system suggest that these
peptides are both independently regulated and differentially regu-
lated by physiological activity, even though all three synthetic
systems may coexist within individual neurons. In the untreated
mouse, far more mossy fiber boutons contain dynorphin and CCK
immunoreactivity than enkephalin immunoreactivity. Following re-
current seizures, the reverse is true: a high density of boutons
contain enkephalin, while fewer dynorphin- and no CCK-immuno-
reactive boutons are found. The seizures seem to push the mossy
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fiber system from “State-A” (enkephalin poor) to “State-B”
(enkephalin rich). Put in these terms, these findings encourage
speculation that individual granule cells might also have a State-A
in which they actively synthesize dynorphin and, in some animals,
CCK; and a State-B in which they actively synthesize enkephalin
and not the other peptides. As suggested earlier, this would
account for the localization of dynorphin B and the proenkephalin
A product BAM 22 within separate granule cells (McGinty 1985),
without leading to the conclusion that there are distinct popula-
tions of granule cells as characterized by their invariant synthesis
of either enkephalin or dynorphin.
Taking this hypothesis one step further, the presence of dense
enkephalin immunoreactivity in a subset of mossy fiber boutons in
the untreated animal may reflect the differences in the recent
physiological activity of their parent neurons. The enkephalin-
immunoreactive neurons, in distinction from the larger group of
granule cells, may have moved into the enkephalin-synthesizing
State-B as a consequence of physiological events occurring days
earlier.
The indication from the seizure data that activity induces enkeph-
alin synthesis may provide some interpretation for the ontogenetic
data as well. As reviewed above, dynorphin and CCK are present
within the hippocampal mossy fibers during the period of synapto-
genesis and well before the morphological elaboration of the mossy
fiber boutons. In contrast, enkephalin does not appear in this sys-
tem until much later. By the size of the mossy fiber boutons first
seen to contain enkephalin, one would estimate that this peptide
does not appear until about a week after synaptogenesis. lt is pos-
sible that enkephalin does not appear within the mossy fibers until
the physiological activity of the granule cells or their afferents is
sufficiently mature to induce synthesis.
The validity of the above suggestions is difficult to assess at the
moment. Most importantly, we do not know whether nonepilepti-
form physiological activity influences the synthesis of enkephalin in
the dentate gyrus granule cells. We do, however, have evidence for
the colocalization of enkephalin and CCK in other mammalian brain
areas (Gall et al. 1987) and for the independent regulation of co-
localized enkephalin and CCK in invertebrates (Petrics-Gesser and
Larsson 1985). There is also a growing body of evidence that co-
localized peptides and classical neurotransmitters are differentially
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and probably independently regulated by physiological activity in
peripheral systems (Black 1984).
Returning from the cellular to the system level, the potential con-
sequence of opposite fluctuations in enkephalin and CCK content in
the mossy fiber system following seizures is very intriguing. CCK
has been demonstrated to be antagonistic to endogenous-opioid-
mediated processes in other systems (Faris et al. 1988). CCK has
also been suggested to have anticonvulsant properties (Kádár et al.
1984) while enkephalin has been demonstrated to induce limbic
seizures when injected into the hippocampus (Elazar et al. 1979).
These factors lead one to speculate that the shift in CCK/
enkephalin balance in the mossy fiber system following seizures
may be of consequence to the future seizure susceptibility of the
structure.
In closing, it might be appropriate to ask if the hippocampus has
served, and continues to hold promise, as a fruitful model system
for the study of opioid peptides in the brain. I suggest that the
answer is yes, but in ways not anticipated 5 years ago. Although
the specific contribution of the endogenous opioid peptides to
synaptic physiology in the hippocampus and elsewhere remains
largely unresolved, we have identified systems and paradigms with
which we can study the physiological regulation of opioid gene
expression in the brain, and possibly resolve mechanisms through
which experience leaves its trace in the operation of neuronal
circuitry.
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The Anatomical Relationship
of Opioid Peptides and Opiate
Receptors in the Hippocampi
of Four Rodent Species
Miles Herkenham and Stafford McLean
lNTRODUCTlON
A commonly held assumption in neurobiology is that drugs and
neurotransmitters bind to postsynaptic receptors located at sites of
termination of central nervous system (CNS) pathways containing
the relevant transmitter. One expectation, therefore, is that auto-
radiographic maps of receptor distributions should closely resemble
(or match) the immunohistochemical maps of terminals of the relat-
ed transmitters. This paper reports a test of that assumption in
the rodent hippocampus, a cortical structure whose laminar organi-
zation has been well characterized for a number of neurochemicai
systems, including opioid peptides and opiate receptors.
Currently, three families of opioid peptides have been identified:
the proenkephalin gene yielding the enkephalins and other carboxy
terminal extended forms, the prodynorphln gene providing the
dynorphins, and the proopiomelanocortin gene providing beta-
endorphin. Extensive work has documented enkephalin and dynor-
phin but not beta-endorphln immunoreactive systems in the rodent
hippocampus.
The existence of three major opiate receptor subtypes in the brain
is now accepted: the mu receptor exhibiting highest affinity for
morphine and related alkaloids, the delta receptor binding enkepha-
lin better than morphine, and the kappa receptor having a high
affinity for ethytketocyclazocine and dynorphin (Lord et al. 1977;
Chang et al. 1979; Chavkin et al. 1982; Corbett et al. 1982).
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In this study, the distributions of mu, delta, and kappa opiate
receptors were determined in the hippocampi of four species of
rodent (squirrel, guinea pig, rat, and hamster) and compared with
the distributions of immunoreactive dynorphln and enkephalin in
each species. Although distributions of the peptides were fairly
similar across species, the distributions of each of the receptor
types showed marked species variations. Moreover, the terminal
and receptor localization patterns did not typically correspond to
each other, leading to the conclusion that different determinants
underlie the distributions of each, After most explanations for
these mismatches are considered and found lacking, it is proposed
that transmitters like the opioid peptides act in a parasynaptic
fashion to diffuse from release sites and bind to receptors on non-
contiguous cells.
lMMUNOHlSTOCHEMlSTRY
The distribution of enkephalin and dynotphin in the anterior hippo-
campus is relatively invariant across the four rodent species. Most
striking is the intense immunoreactivity in the mossy fiber system
(figure 1 on pp. 36 and 37). In all species, mossy fibers immuno-
reactive for both peptides course from the dentate hilus into the
stratum lucidum of the CA3 and CA2 regions. Here, the immuno-
reactivity is punctate and dense, indicative of a terminal zone.
in addition, isolated dynorphin-positive fibers are present in the
stratum radiatum, and sparse enkephalin fibers are found throughout
the CA fields. The dentate molecular layer contains occasional
dynorphin- and enkephalin-positive processes which often can be
traced back to immunoreactive granule cells.
At these rostral hippocampal levels, a dense plexus of enkephalin
fibers in the hamster and rat straddles the hippocampal fissure,
occupying superficial parts of both the dentate molecular layer and
stratum lacunosum-moleculare of CA1 (figure 1). This immuno-
reactivity represents the enkephalinergic component of the perfo-
rant path, which originates in the entorhinal cortex (Fredens et al.
1984).
RECEPTOR AUTOGRAPHY
The distributions of the opiate receptor subtypes mu, delta, and
kappa exhibit a variable relation to the distributions of endogenous
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opioid peptides and considerable diversity among species. However,
within a species, mu and kappa receptors are similarly distributed
and, except for the rat, have a pattern which is generally the in-
verse of the delta pattern.
Squirrel
The dentate gyrus contains the greatest density of both mu and
kappa receptors (figure 1). Another peak of dense mu and kappa
receptors is found in the stratum lucidum of the CA3/CA2 fields.
The pattern of delta receptors in the squirrel is strikingly different
from the kappa and mu distributions. First, the stratum lucidum is
notable for its lack of labelling. Second, delta sites are conspicu-
ously absent from all cell layers. Third, in contrast to the low
levels of mu and kappa receptors in the CA1 field, delta receptors
are dense there.
Guinea Pig
In the guinea pig, the stratum lucidum has the densest kappa label-
ling. The distribution of mu receptors is similar to that of kappa
receptors, but there are far fewer mu sites.
The delta binding pattern differs from the mu and kappa patterns.
Dense binding is present in CA1 in all layers but the pyramidal cell
layer and the superficial part of the stratum lacunosum-moleculare.
Within the CA3 Reid, the region of the mossy fiber terminal zone
has the lowest delta receptor density in the anterior hippocampus.
The dentate gyrus molecular layer is characterized by few delta
receptors, though a band of higher density is found in its most
superficial position, bordering the hippocampal fissure. The hilar
region is moderately labelled and shows elevated binding subjacent
to the granule layer.
Hamster
The hamster has kappa receptors densely and selectively distributed
in the two locations that also contain intense peptide immuno-
reactivity, namely the dentate hilus and the stratum lucidum (figure
1). In addition, a moderate kappa receptor density fills the re-
maining dentate gyrus. The mu pattern is similar, but the density
is much lower throughout. Mu and kappa binding is not detected
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FIGURE 1. Distribution of opioid peptides and receptors in the
hippocampi of four rodent species
NOTE: Immunoreactivity was performed using the avidin-biotin technique, and
the receptor distributions were derived from autoradiographic film
images. For immunohistochemistry, frozen and cut fixed sections were
Incubated in antisera against dynorphin B (1:2,000) (E. Weber) or leu-
enkephalin (1:1,000) (Immunonuclear). For receptor autoradiography,
fresh frozen brains were cut and thaw-mounted onto slides. For mu
binding, slides were incubated for 90 minutes at 25 °C in tris buffer
with 2 nM [3H]D-Ala2, MePhe4,Gly-ol5 enkephalin. For delta binding,
slides were Incubated in tris buffer and 30 nM oxymorphone with 4.8 nM
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[3H]O-Ala2,D-Leu5-enkephalin. For kappa binding, slides were trans-
ferred to MOPS buffer with 1 µM BIT and 1 µm FIT and incubated for
30 minutes at 25 °C. BIT and FIT are, respectively, selective mu and
delta opiate receptor irreversible acylating agents (Rice et al. 1953).
The sections were then incubated for 3 hours at 0 °C in phosphate
buffer containing 0.4 M NaCl and 7 nM [3H]bremazocine. Abbreviations:
H, hilus; SG, stratum granulosum; HF, hippocampal Assure; SLM, stratum
lacunosum-moleculare; SR, stratum radiatum; SP, stratum pyramidale; SO,
stratum oriens; SL, stratum lucidum. Asterisks mark locations of SP.
Arrowheads mark location of HF. Calibration bar measures 450 µM for
squirrel and guinea pig and 250 µM for rat and hamster.
SOURCE: McLean et al. 1987.
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in the CA1 field. In contrast, delta receptors show virtually the
opposite pattern; they are lowest in the dentate gyrus and densest
in hippocampal regio superior, where they occupy all layers but the
pyramidal. In CA3, the stratum lucidum is very delta receptor
sparse.
Rat
The rat differs from the previous three species in two ways (figure
1). First, the mu, kappa, and delta receptor distributions are all
similar to each other. Second, the zones of high density are locat-
ed in and adjacent to the pyramidal and granule cell layers. The
pyramidal layer is enriched with all three subtypes, though the re-
ceptor band actually occupies the deep half of the pyramidal layer
and extends into the stratum oriens. Mu and kappa receptors have
a denser and wider band in CA2/CA3 than in CA1 , and they show
an abrupt shift in density at the border. Delta sites display no
major density shifts throughout the CA fields. Mu sites are selec-
tively sparse in the stratum lucidum (figure 1). The three receptor
subtypes occupy the dentate gyrus in moderate densities. Mu and
kappa sites show a peak of higher density in the vicinity of the
granule cell layer.
DISCUSSION
The results of the present study show that there is no obvious
relationship between the locations of opioid peptides and opiate
receptors in the hippocampus, and this “mismatch” is the main focus
of the present study. In essence, the organization of the enkepha-
lins and dynorphins is fairly consistent among the four rodent
species examined, whereas the distribution of the opiate receptor
subtypes is variable (figure 1). While both opioid and peptide
terminals and opiate receptors display patterns that closely conform
to the regional and laminar morphology of the hippocampal forma-
tion, the organizations of these pre- and postsynaptic elements are
clearly different from each other.
This does not mean that very good correspondence between opioid
peptides and receptors cannot be obtained. In the guinea pig and
hamster, mu but especially kappa receptors are densely located in
precisely the same locations (dentate hilus and stratum lucidum)
that show intense opioid peptide immunoreactivity. Similarly, in
the hamster and rat, the receptors in the outer third of the
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dentate molecular layer and the adjacent stratum lacunosum-
moleculare are aligned with enkephalinergic fibers, presumably
terminals of the lateral perforant pathway. However, the dense
distributions of kappa and delta receptors in the dentate molecular
layers of the squirrel and guinea pig, respectively, are not matched
by a corresponding density of peptides. Unlike the other rodents
studied, the rat shows binding peaks for all three receptor subtypes
in the regions of the cell body layers where peptides are not de-
tected; conversely, kappa but especially mu receptors are practically
absent in the peptide-rich mossy fiber terminal zone. Thus, indi-
vidual instances of matches of peptides and receptors are present,
but no consistent pattern of correspondence occurs across species.
In fact, for all species examined, the delta receptors have unique
patterns which typically show an inverse relationship with the pep
tide densities and distributions.
Physiology
Administration of opiate alkaloids and peptides both in vivo (Nicoll
et al. 1977; Chou and Wang 1977; Henriksen et al. 1982) and in
slice preparations in vitro (Dunwiddie et al. 1980; Haas and Ryall
1980; Lee at al. 1980; Dingledine 1981) consistently produces in-
creased hippocampal pyramidal cell activity. It has been concluded
that the opiates, rather than acting directly on pyramidal cells, act
instead to remove a tonic inhibitory input to the pyramidal cells
via occupation of receptors on interneurons (Zieglgänsberger et al.
1979; Dunwiddie et al. 1980; Lee et al. 1980).
Within the CA1 field of the rat, microiontophoretic mapping studies
have demonstrated that the stratum pyramidale and stratum oriens
are sites most sensitive to the administration of enkephalins
(Dingledine 1981). This is consistent with the elevated levels of all
three opiate receptor subtypes in these layers.
Opiate receptor localization and opiate physiology create expecta-
tions about opioid peptide terminal locations, but these are not met
by the relatively restricted localization of the peptides in the
mossy fiber system, which is known to convey excitatory impulses
to CA3 pyramidal cells, possibly using glutamate as the transmitter
(Storm-Mathisen and lversen 1979; Altschuler et al. 1985). In the
stratum lucidum, mossy fibers which contain the highest density of
opioid peptides in the hippocampus (Chavkin et al. 1985; Zamir et
al. 1985) terminate selectively on pyramidal cell dendrites (Hamlyn
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1962). Because opiates appear to exert their inhibitory effects on
interneurons, opioid-containing processes should terminate on inter-’
neurons rather than pyramidal cell dendrites. However, there is no
evidence that any mossy fibers make selective inhibitory contacts
with interneurons in the stratum lucidum of CA3. Thus, there is
no currently known aspect of mossy fiber anatomy or physiology
that fits with our knowledge of the major opiate actions in the
hippocampus.
Mismatch Implications
The mismatches between opiate receptor locations and sites of re-
lease of opioid peptides at nerve terminals noted here for the
hippocampus are part of a much larger and more general phenome-
non that occurs for ail well-characterized neurotransmitter/receptor
systems. We have pointed out (Herkenham and McLean 1988;
Herkenham 1987) that there is a failure of correspondence, a mis-
match, between the locations of nerve terminals and receptors
throughout the central and even peripheral nervous system for all
neuropeptides, monoamines (norepinephrine, dopamine, and sero-
tonin), and “fast” transmitters (gamma-aminobutyric acid, acetyl-
choline, and glutamate). Explanations for the mismatches can be
put into four categories:
(1)
(2)
(3)
(4)
Typically, it has been assumed that mismatches represent
technical failures and/or incomplete knowledge of the full
endowment of transmitters or receptors within a family of
chemically related substances.
It has also been pointed out that we should not expect a
match, since transmitters and receptors represent pre- and
postsynaptic elements of different neurons which may express
their features throughout their processes and not just at the
sites of contact (Kuhar 1985).
Biochemical possibilities for the discrepancies include occupied
receptors (not available for binding by virtue of prebound en-
dogenous ligand), spare receptors, and nonfunctional receptors.
More recently, we have stressed the likelihood that many re-
ceptors, especially those to which the endogenous ligand binds
with high affinity, are not located at synapses and may be
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sites of action of transmitters released from a distance
(Herkenham and McLean 1986; Herkenham 1987).
The present results can be used to test the various explanations for
the mismatches. Addressing the issues in the first category, we
have used the most sensitive and optimal histological techniques
currently available and have provided quantitative analysis of the
receptors using previously validated binding conditions. We have
used markers that recognize the predominant forms of endogenous
hippocampal opioid peptides and all of the major opiate receptor
subtypes, so that it is unlikely that undiscovered ligands or recep-
tors exist which would significantly alter the presently described
relationships. Even if a low-affinity synaptic receptor is discovered
that is selectively localized to terminal zones, we would still have
to consider the roles of the more widely distributed and mismatched
high-affinity sites.
Consideration of hippocampal anatomy sheds light on the second
category. Given the horizontal stratification of the receptors and
the vertical alignment of hippocampal dendrites, it is clear that, if
receptors are localized on hippocampal neurons, then they are con-
fined to restricted zones along the length of the dendritic tree. lf
some proportion of the receptors is located on afferent axons
rather than on dendrites, then this population of receptors appears
to be concentrated at axon terminals, as the major afferent fiber
tracts do not show commensurate receptor densities. Thus, cells
and fibers both show discrete receptor localization, making unlikely
the suggestion that receptors in one hippocampal location are cyto-
plasmic and in transit to another location (Stengaard-Pedersen
1983), or that they reflect the ceil’s inability to concentrate bind-
ing sites.
Transmitters, of course, are localized by immunocytochemistry
throughout cell bodies, axons, and terminals, and this can be a
basis for a mismatch if the sites of terminal release cannot be da
termined. Opioid peptide immunohistochemistry indicates that the
major hippocampal terminal zone lies in the stratum lucidum,
whereas scattered fibers with varicosities suggest additional release
sites in the dentate and CA fields. Another source of opioid-
peptide-containing terminals is the perforant path (Gall et al. 1981;
Stengaard-Pedersen et al. 1981; Tielen et al. 1982; Fredens et al.
1984), but this provides enkephalin fibers predominantly to more
caudal (temporal) parts of the hippocampus rather than to the
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rostral (septal) part examined in this study. Perforant path termi-
nals are localized to the superficial parts of the hippocampai and
dentate molecular layers. Thus, for the hippocampus, the major
sites of peptide release are known, and these taken together are
the basis for the present claim that there is no correlation between
their locations and the distributions of the receptors.
Each of the various biochemical explanations for the mismatch in
the third category can be put in perspective by the present results.
The possibility of receptor occupation by the endogenous ligand is
prevented by preincubating sections in buffer containing high con-
centrations of Na+, which causes dissociation of endogenous ago-
nists from the receptors (Garzón et al. 1984). A more compelling
argument is that we show instances of dense mu and kappa recep-
tors in the stratum lucidum, providing an excellent correspondence
of dense receptors in a location where endogenous enkephalin and
dynorphih are apparently released in high concentrations.
The possibility of spare receptors is an intriguing one that deserves
further study. Spare receptors can be responsible for an amplifica-
tion of biological response, which might be useful in locations
where ligands exist in low concentrations. If spare receptors
“explain” some of the hippocampal mismatches, then they must exist
in high proportions in some hippocampal regions and not in others.
As argued elsewhere for the substance P (Mantyh et al. 1984,
Herkenham and McLean 1986; Herkenham 1987) and alpha-1-
adrenergic systems (Johnson and Minneman 1985), regional
correlations between receptor density and amplitude of biological
response have not documented differential distributions of spare
receptors. However, this line of inquiry could be fruitful in the
opiate system.
Finally, within this third category, receptors are seen by some
workers as either nonfunctional or “merely” drug-binding sites.
This is an implausible view in light of the precision with which
they are distributed, the metabolic expense and synthetic machinery
required to maintain them, and the proven functionality in physio-
logical studies showing responses to drug application localized in
sites, such as CA1, where the concept of nonfunctional receptors
might be most appealing because of a paucity of the endogenous
ligand. In fact, within CA1 of the rat, the discrete distribution of
opiate receptors in stratum pyramidale and adjacent stratum oriens
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corresponds precisely with D-ala2-D-leu5-enkephalin (DADLE)-
sensitive sites most effective in enhancing the population spike
(Dingledine 1981).
The fourth category of explanations is centered around the possi-
bility that many receptors are not localized to synapses. There is
ample evidence for this hypothesis. In a recent electron micro-
graphic autoradiography study, Hamel and Beaudet (1984) found that
only a small percentage (7 percent) of mu opiate receptors in rat
striatum are located at junctional contacts satisfying the usual
criteria for synapses. Most sites were at nonjunctional, hence non-
synaptic, contacts between neuronal elements. lt is well known
that cell-to-ceil communication in the autonomic nervous system
occurs without synapses (Merillees et al. 1983). Presynaptic modu-
lation of neurotransmitter release by ehdogenous ligand in the CNS
is likely to be nonsynaptic, insofar as electron micrographic studies
almost never show axoaxonic synapses at nerve terminals. Diffu-
sion of transmitter to distant sites has been documented in the
peripheral nervous system (Jan and Jan 1983; Kravitz et al. 1983).
The possibility that nonsynaptically located opiate receptors are
targets of opioid peptides released from distant sites may shed light
on a fundamental question: Why does the CNS utilize so many opi-
oid peptides and receptor subtypes? One hypothesis, promoted by
several laboratories and based on relative affinities and potencies in
bioassays, is that a given peptide is targeted to a particular type
of opiate receptor. An alternative hypothesis is that many forms
of opioid peptides can interact with each of the receptor subtypes:
thus, source and availability of ligand, ligand stability, receptor
microenvironment, as well as kinetics of the receptor/ligand inter-
action may play important roles in intercellular information
transfer.
The cerebrospinal fluid (CSF) is a possible conduit for diffusion of
endogenous opioid peptides to targets, such as the hippocampus,
that are close to the ventricles. Ventricular administration of
beta-endorphin causes hippocampal seizure activity by diffusion of
this endogenous ligand into the hippocampal neuropil (Henriksen et
al. 1978). Seizure activity itself causes release of an endogenous
opioid material into the CSF, and this material diffuses to distant
neuronal sites to alter the threshold for subsequent seizures
(Tortella and Long 1985). The sources and nature of the endoge-
nous neurochemicais and the precise targets for the opiate effects
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are currently unknown, and speculation about the role that hippo-
campal opiate receptors might play in generation or inhibition of
seizures is beyond the scope of the present data. However, we can
speculate that dense high-affinity opiate receptors in the hippo-
campus may be localized to participate in cell-to-cell communication
transmitted nonsynaptically at very low ligand concentrations. This
mechanism is consistent with proposed roles of opiates as neuro-
modulators of pyramidal cell activity.
.
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Seizure-Induced Alterations in the
Metabolism of Hippocampal Opioid
Peptides Suggest Opioid Modulation
of Seizure-Related Behaviors
Jau-Shyo Hong, Jacqueline F. McGinty, Laura Grimes,
Tomoyuki Kanamatsu, Johnny Obie, and Clifford L. Mitchell 
INTRODUCTlON
Endogenous opioid peptides appear to play an important role in the
regulation of brain excitability, especially in the seizure-sensitive
hippocampus. Proenkephalinderived peptides have a unique excita-
tory action when iontophoretically applied to pyramidal cells of the
hippocampus, whereas in most other brain areas these peptides
manifest inhibitory actions (Nicoil et al. 1977). Electroencephalo-
graphic (EEG) recordings have indicated that intracerebroventricular
(ICV) or intrahippocampal injections of enkephalins or beta-
endorphin have either proconvulsant (Elazar et al. 1979; Henriksen
et al. 1978; Urca et al. 1977) or anticonvulsant (Tortella and Cowan
1982) properties depending on experimental conditions (Frenk 1983).
Unlike proenkephalin- or proopiomelanocortin-derived peptides,
however, prodynorphin-related peptides have a more complex
electrophysiological profile. Intracerebroventricular dynorphin does
not induce epiieptiform activity in the rat, and single-unit and field
potential studies show mixed effects on CA3 neuronal excitability
with more inhibitory responses than are seen with the enkephalins
(Henriksen et al. 1982; Walker et al. 1982; Gruol et al. 1983;
Henriksen et al., this volume; Chavkin et al., this volume). Sub
cutaneous or ICV injection of the specific kappa agonist U50 488
provides protection against certain electroconvulsive shock (ECS)-
induced seizures in rats, suggesting an anticonvulsant role of
endogenous kappa agonists such as dynorphin (Tortella et al. 1986).
Seizure activity exerts profound effects on the metabolism of opioid
peptides in certain seizure-sensitive brain regions such as the
hippocampus, amygdala, and substantia nigra. We have employed
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different models of seizures, such as ECS (Hong et al. 1979;
Yoshikawa et al. 1985; Kanamatsu et al. 1988a), amygdaloid kindling
(McGinty et al. 1988), or kainic acid (Hong et al. 1980; Kanamatsu
et al. 1986b), to study the interrelationship between brain opioid
peptides and seizures. It is the purpose of this chapter to review
our progress in this area.
ELECTROCONVULSIVE SHOCK
Effects of Repeated ECS on the Metabolism of Enkephalins
lt has been suggested that endogeneous opioid peptides may mediate
some ECS-elicited behavioral alterations, including analgesia, retro-
grade amnesia, changes in seizure threshold, and postictal depres-
sion, since these behaviors can be prevented or altered by
pretreatment with opiate antagonists (Carrasco et al. 1982; Holaday
. and Belenky 1980; Tortella and Cowan 1982; Urca et al. 1981; Urca
et al. 1988). The increase in met5-enkephalin-like immunoreactivity
(ME-LI) in certain limbic areas of the rat brain, such as the sep-
tum, amygdala, nucleus accumbens, hypothalamus, and hippocampus
(figure 1 and table 1), produced by repeated ECS treatment, also
suggests a role for ME in the behaviors listed above. In contrast,
beta-endorphin content in the hypothalamus was not altered by re-
peated ECS, suggesting specific ME involvement (Hong et al. 1979;
Kanamatsu et al. 1986a). In order to determine whether the in-
crease in ME-LI elicited by repeated ECS was due to an increase in
the biosynthetic activity of enkephalin-containing neurons, we
measured the abundance of messenger RNA (mRNA) coding for pre-
proenkephalin A, using both in vitro cell-free translation and blot
hybridization using a complementary DNA (cDNA) clone coding for
preproenkephalin A derived from rat brain. The results demon-
strated that repeated ECS increased the abundance of mRNA coding
for preproenkephalin A in the hypothalamus (Yoshikawa et al. 1985)
and hippocampus (Li et al., in preparation). This finding suggests
that ECS increases the metabolic rate of ME-LI and also may trig-
ger a large release of this opioid peptide from nerve terminals.
This possibility was further supported by our recent report that
repeated ECS downregulates the opioid receptors in rat brain
(Nakata et al. 1985). Ten consecutive daily ECS treatments caused
a reduction of mu and delta receptor binding in the hypothalamus,
hippocampus, and caudate nucleus, but not in the frontal cortex and
brain stem. These changes of opioid receptor binding were not ob-
served in rats receiving a single ECS. Scatchard analysis revealed
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FIGURE 1. Hippocampal met5-enkephalin and dynorphin A (1-8)
levels 1 day after 1 to 10 daily ECS treatments
NOTE: (A) Met5-enkephalin levels were significantly increased 1 day after 6 or
10 daily ECS treatments (p<0.05). (B) Dynotphin A levels were signifi-
cantly decreased 1 day after 3, 6. or 10 ECS treatments (p<0.01).
SOURCE: Kanamatsu et al. 1986a. Copyright 1986, Society for Neuroscience.
that ECS-induced reduction of opioid receptor binding was due to a
decrease in the binding but not to a change in the binding affinity.
Similar to the changes in ME-LI, time-course studies showed that,
7 days after the end of 10 consecutive ECS treatments, both mu
and delta receptor binding remained lower than those of sham con-
trols, but the effect disappeared in 2 to 3 weeks. These observa-
tions are consistent with the hypothesis that ECS treatments in-
crease the release and biosynthesis of opioid peptides in certain
brain regions, which in turn downregulates the opioid receptors
(Nakata et al. 1985).
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TABLE 1. ECS-induced changes in hippocampal opioid peptide
levels
ECS Treatment Dynorphin A Met5-enkephalin
5 Minutes After:
1 ECS -40% ±0%
1 Day After:
1 ECS
3 ECS
6-10 ECS
+10% ±0%
-30% ±0%
-70% +40%
2 Weeks After:
6-10 ECS ±0% ±0%
Effects of Repeated ECS on the Metabolism of Dynorphins
We have found that the metabolism of prodynorphin-derived pep-
tides is also very responsive to repeated ECS treatments in dif-
ferent brain regions (Kanamatsu et al. 1986a). Ten daily ECS
treatments caused a significant increase in dynorphin A (1-8)-like
immunoreactivity (DN-LI) in most limbic-basal ganglia structures
including the hypothalamus, striatum, and septum. These results
are very similar to those for ME-LI. However, the ECS treatments
decreased DN-LI in the hippocampus by 64 percent, while ME-LI
increased 40 percent (figures 1 and 2 and table 1). A possible
anatomical basis for this was revealed by immunocytochemistry,
which showed that dynorphin A (1-8) immunostaining was depleted
in the mossy fiber pathway, and enkephalin immunostaining was in-
creased in the perforant pathway. The differential responsiveness
of enkephalin- and dynorphin-containing neurons in the hippo-
campus can be observed in other seizure models including kainic
acid and amygdaloid kindling (see below). These observations
suggest that different mechanisms may regulate these two opioid
peptide systems in the hippocampus, and that they play different
51
FIGURE 2. Hippocampal opioid peptide levels 1 day and 28 days
after amygdaloid kindled seizures
NOTE: (A) ME-LI is increased significantly (p<0.05) 1 day after reaching two
consecutive stage 5 seizures only. (B) DN-LI is decreased significantly
(p<0.001) 1 day after reaching stage 5 seizures only.
SOURCE: McGinty et al. 1986, Copyright 1986, Elsevier Scientific Publishers
Ireland Ltd.
roles in mediating hippocampal excitability by interacting with dif-
ferent receptor subtypes.
Effects of a Single ECS on the Metabolism of Enkephalins and
Dynorphins
Recently, we examined the effects of a single ECS on brain opioid
peptides. Time-course studies revealed that, within 15 minutes
after a single ECS, there was a 40 percent decrease of DN-LI in
the hippocampus, but no change was found in the other brain
regions examined, including the hypothalamus, striatum, and brain
stem (Takeuchi et al., in preparation). Furthermore, levels of ME-
LI, substance P, and cholecystokinin (CCK) (1-8) were not altered
in the hippocampus, suggesting that hippocampal dynorphin-
containing neurons are most sensitive to ECS, and changes in
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dynorphin metabolism are most correlated with ECS-elicited changes
in seizure threshold or retrograde amnesia.
KINDLING-INDUCED SEIZURES
Effects of Amygdaloid Kindling on the Metabolism of Enkephalins
and Dynorphins
Kindling is an experimental model of temporal lobe epilepsy in
which initially subthreshold stimulations result in progressively more
intense seizure activity (stages 1 to 4), until a generalized (stage 5)
seizure occurs (Goddard 1967; Racine 1972). Recent studies have
suggested that two dynorphin-rich structures, the hippocampal for-
mation and the substantia nigra, are involved in the development of
kindling and expression of a fully kindled seizure, respectively
(McNamara et al. 1966). There is, however, no evidence that
alterations in opioids or other neurotransmitters or receptors are
responsible for the permanence of the kindling phenomenon
(Woodbury 1984).
Several lines of evidence have indicated involvement of endogenous
opioid peptides in modulating amygdaloid-kindled seizures. Nalox-
one, a stereoselective opioid antagonist, has been reported to facil-
itate amygdaloid kindling in rats (Hardy et al. 1980). In addition,
the duration of postictal depression can be altered by opioid ago-
nists and antagonists (Frenk et al. 1979). Enkephalin has been
reported to be increased in whole rat brain (Vindrola et al. 1981),
and dynorphin has been observed to be increased in rabbit hippo-
campus 1 day after reaching stage 5 seizures (Przewlocki et al.
1983). In order to construct a time course of opioid peptide
changes during and after amygdaloid kindling, we examined rats 1
day after reaching subconvulsive stage 3 seizures, and 1 day and 4
weeks after two consecutive stage 5 seizures (table 2). One day
after stage 3 seizures, no significant change in opioid peptide levels
was observed by radioimmunoassay (RIA) or immunocytochemistry
(ICC). In contrast, 1 day after two consecutive stage 5 seizures,
there was a 50 percent increase in ME-LI in the projection from
the entorhinal cortex to hippocampal pyramidal cells (the temporo-
ammonic component of the perforant pathway) and a 70 percent de-
crease in DN-LI in the mossy fibers of the hippocampus (McGinty
et al. 1986). The only other change was an increase in the
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TABLE 2. Kindling-induced changes in hippocampal opioid
peptides
Site Dynorphin A Met5-enkephalin
Amygdala
1 Day After:
Stage 3
Stage 5
28 Days After:
Stage 5 ±0%
Prepiriform
5 Minutes After
Stage 2
Stage 5
1 Day After:
Stage 2
Stage 5
6 Weeks After:
Stage 2
Stage 5
±0%
-71%
20%
±0% +34%* +167%***
-23% +30%* +237%***
+13%
-12%
±0%
±0%
±0%
+43%
HPC ERC
+41%** +221%***
±0% +84%*
±0% ±0%
±0% ±0%
*p<0.05
**p<0.01
***p<0.001
NOTE: HPC=hippocampus: ERC=entorhinal cortex.
immunostaining of dynorphin in the substantia nigra pars reticulata,
a structure implicated in the regulation of kindled seizure thresh-
olds (McNamara et al. 1984). Normal levels of both peptides in the
hippocampus and substantia nigra returned by 4 weeks after com-
pletion of kindling. A recent study by Naranjo et al. (1986)
indicates that the increase in the levels of hippocampal enkephalin
after amygdaloid kindling is due to an increase in the biosynthesis
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of this peptide. Therefore, while opioid peptides are not involved
in the permanence of the kindling phenomenon, kindling-induced
seizures stimulate different changes in the metabolism of dynorphin
and enkephalin, suggesting separate regulation of each peptide in
states of hyperexcitation.
Effects of Prepiriform Cortex Kindling on the Metabolism of
Enkephalin and Dynorphin
In order to further examine the role of opioid peptides In the
development and expression of seizures, we have determined the
levels of opioid peptides in different brain regions kindled by stim-
ulation of the deep prepiriform cortex (DPC) once every hour until
stage 2 or stage 5 seizures occurred. The DPC has recently been
identified as a critical epileptogenic site in the brain (Piredda and
Gale 1965). In contrast to the large decrease in hippocampal
dynorphin levels 1 day after reaching stage 5 amygdaloidkindled
seizures, DN-LI was slightly but significantly elevated in DPG
kindled hippocampus 5 minutes after stage 2 seizures, and slightly
depressed 5 minutes after stage 5 seizures (table 2). However,
there was a large increase in ME-LI in the entorhinal cortex (ERC)
and a moderate increase in the hippocampus (table 2) among other
areas 5 minutes or 24 hours after reaching stage 2 seizures, and 5
minutes after two consecutive stage 5 seizures (Zhao et al., in
preparation). Twenty-four hours after reaching stage 5 seizures,
the ME-LI increase in the ERC had moderated, and the elevation in
the hippocampus had disappeared. These data suggest that the
development of prepiriform-kindled seizures has more of an effect
on enkephalin in the ERC than on dynorphin in the hippocampus.
These data are supported by the observation that an ICV injection
of beta-fulnaltrexamine (a long-lasting mu receptor antagonist),
reduced the number of DPC stimulations required to reach stage 5
seizures by about 50 percent (Lee et al., unpublished observations).
These observations are consistent with previous reports which pro-
mote an anticonvulsant role of opioid peptides in electrically
stimulated seizures (Hardy et al. 1980; Frenk et al. 1979).
KAINIC-ACID-INDUCED SEIZURES
Kainic acid (KA) is an excitatory amino acid which causes hippo-
campal epileptiform activity and motor seizures. When applied
intracerebrally, it is most toxic to hippocampal pyramidal cells in
fields CA3 and CA4 (Nadler et al. 1978), which are innervated by
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enkephalin- and dynorphincontaining mossy fibers. Several labora-
tories have employed this neurotoxin to provide a model for human
temporal lobe epilepsy (Ben-Ari 1985; Nadler 1981). Administration
of KA to rats by various routes elicits a repertoire of epileptiform
behaviors that depends upon the dose and the particular route of
administration. Systemic injection and injection into the amygdala
both produce a syndrome consisting mostly of wet dog shakes
(WDS) followed by gnawing, sniffing, and masticatory movements,
followed by repetitive head bobbing, rearing, forelimb clonus, and
sudden loss of upright posture (Ben-Ari et al. 1980). Hippocampal
injections of KA produce WDS, bilateral proptosis, forelimb clonus,
and episodes of hyperactivity characterized by circling away from
the injected side (Schwartz et al. 1978). Lower doses of intra-
ventricular KA cause WDS, but higher doses of KA produce tonic-
clonic seizures (Lanthorn and lsaacson 1978). Usually, the seizures
last 3 to 6 hours depending on the doses used.
Effects of KA on the Metabolism of Hippocampal Enkephalins and
Dynorphins
We have employed KA as a tool to perturb the metabolism of opioid
peptides in the hippocampus so we could study in detail the molec-
ular mechanisms regulating the biosynthesis, processing, and release
of these peptides. Initially we found that, 2 days after a single
intraventricular or intrastriatal dose of KA, the level of ME-LI in-
creased significantly in the hippocampus and remained elevated for
2 weeks, as demonstrated by RIA (Hong et al. 1980). Subsequently,
we found that leu5-enkephalin-like immunoreactivity detected by
RIA and ICC was increased in mossy fibers and perforant path fi-
bers, whereas the level of DN-LI was unchanged in mossy fibers 4
days after KA administration (McGinty et al. 1983). These altera-
tions were our first indication that the metabolism of dynorphin
and enkephalin could be differently regulated, not only in the
same brain structure but in the same pathway.
Recently, we assayed hippocampal opioid peptides by RIA and ICC
at early time points after a single intrastriatal injection of KA
(Kanamatsu et al. 1986b; figure 2 and table 3). Three to six hours
after KA administration, when recurrent seizures were still appar-
ent, DN-LI in mossy fibers was depleted 70 percent, and ME-LI in
mossy fibers and in the perforant path was depleted by 30 to 40
percent. By 24 to 48 hours, the levels of both peptides had risen
above normal, with DN-LI peaking at 48 hours at 171 percent of
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normal, and ME-LI at 270 percent of normal. However, by 72
hours, ME-LI levels had risen to 300 percent of normal, especially
in the mossy fibers, while DN-LI in the mossy fibers had returned
to normal. The reduction in DN-LI and ME-LI within 3 to 6 hours
of KA administration suggests an increase in the release of these
peptides during the seizure period.
TABLE 3. Kainic-acid-induced changes in hippocampal opioid
peptide levels
Kainic Acid
(Intrastriatal) Dynorphin A Met5-enkephalin
3 hours
8 hours
24 hours
48 hours
72 hours
-40% -30%
-70% -40%
+35% +95%
+65% +170%
± 0 % +200%
To determine whether the increase in hippocampal ME-U elicited
by KA reflected changes in ME biosynthesis, levels of mRNA coding
for preproenkephalin (mRNAenk) and cryptic ME-LI cleaved by en-
zyme digestion from preproenkephalin were measured (figure 3).
Following the convulsant period (8 hours), mRNAenk was 400 per-
cent of control, and by 24 hours, cryptic ME-LI was 300 percent of
control. Increases in native and cryptic ME-LI and mRNAenk were
also noted in the entorhinal cortex but not in the hypothalamus or
uninjected strlatum. Our data suggest that KA-induced seizures
cause an increase in ME release, followed by a compensatory in-
crease in ME biosynthesis in the hippocampus and entorhinal
cortex.
The finding that hippocampal mRNAenk was increased following KA
administration is consistent with our previous finding that protein
synthesis inhibition by cycloheximide attenuated the late increase in
hippocampal ME levels of KA-treated animals without affecting ME
levels of controls (Hong et al. 1980). Work is under way in our
laboratory to determine the effects of KA on preprodynorphin
mRNA biosynthesis. It is likely that our mRNA studies will indi-
cate an increase in KA-induced dynorphin biosynthesis because
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FIGURE 3. Hippocampal opioid peptide and mRNA levels after
intrastriatal kainic acid administration
NOTE: (A) Levels of cryptic and native met5-enkephalin and mRNA coding for
preproenkephalin 3 to 72 hours after kainic add. (B) Levels of
dynorphin A (1-8) 3 to 72 hours after kainic add.
SOURCE: Kanamatsu et al. 1986b, Copyright 1986, Society for Neuroscience.
cycloheximide, coadminlstered with intra-amygdaloid KA, has been
shown to block the late increase in hippocampal dynorphin immuno-
reactivity, indicating that proteln synthesis is necessary for the
effect to occur (Larson et al. 1963).
Possible Roles of Hippocampal Opioid Peptides in KA-Induced WDS
Several studies indicate that release of enkephalins from neurons
either within or afferent to the hippocampal formation is critical to
KA-induced WDS. ICV injections of enkephalin (Leybink et al.
1978; Wei et al. 1977; Drust and Connor 1983), beta-endorphln
(Bloom et al. 1976), or kainic acid (Lanthorn and lsaacson 1978)
cause naloxone-reversible WDS, suggesting that both agents produce
WDS by actions at opiate receptors. Electrolytic lesions of the
CA3 but not the CA1 region of the hippocampus attenuate WDS
produced by ICV injections of KA (Isaacson and Lanthorn 1981),
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suggesting that WDS-producing agents act on CA3 neurons rather
than on their CA1 targets. In view of the release of both enkeph-
alin and dynorphin when hippocampal mossy fibers are activated
(Chavkin et al. 1983), we have carded out a series of experiments
to distinguish the possible roles of opioid peptides In the expression
of WDS (Grimes et al., in press).
First, we have confirmed that pretreatment with naloxone attenu-
ates KA-elicited WDS. We injected into rats 2.5, 5.0, or 10.0
mg/kg of naloxone intraperitoneally. Five mg/kg of naloxone re-
duced the number of KA-induced WDS by approximately 50 percent.
To determine which opioid peptide participates in KA-induced WDS,
we injected ICV antisera against either met5-enkephalin or dynor-
phin A (1-8) 4 minutes before KA was administered subcutaneously.
Antisera against met5-enkephalln, but not dynorphin A (1-8), signif-
icantly attenuated WDS. These data indicate that enkephalin, but
not dynorphin, may be associated with KA-induced shaking
behavior.
The cellular basis for KA- and opioid-induced WDS was explored by
injecting D-ala2-D-leu5-enkephalin (DADLE) and dynorphin A (1-8)
into ventral or dorsal hippocampus. Ten µg of DADLE injected
into ventral, but not dorsal, hippocampus elicited 50 to 100 WDS
within a 20-minute period, whereas the same dose of dynorphin
elicited less than 10 WDS.
Finally, colchicine injections into ventral hippocampus abolished
KA-induced WDS but not seizures. We injected colchicine, a cyto-
toxin which selectively destroys dentate granule cells, into dorsal
and/or ventral hippocampus to determine which part of the hippo-
campus is important for the expression of KA-induced WDS. Col-
chicine caused equivalent decreases (81 percent) of ME-LI in dorsal
and ventral hippocampus; however, the concentration of ME-Li was
nearly four times greater in ventral than in dorsal hippocampus.
Therefore, colchicine caused a greater absolute ME-LI decrease in
the ventral than in the dorsal region of this structure. Immuno-
cytochemical and histological data showed that the enkephalin de-
crease was largely attributable to a destruction of dentate granule
cells and the concomitant reduction in staining of the mossy fiber
axons.
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Following KA administration, WDS were not observed in rats with
colchicine-induced lesions of the ventral hippocampus. Lesions
restricted to the dorsal hippocampus caused a nonsignificant atten-
uation of KA-induced WDS. These studies suggest that the ventral
hippocampus is an important site for KA-induced WDS. The far
greater concentration of enkephalin in ventral than in dorsal hippo-
campus offers an explanation of why wlchicine lesions of this re-
gion were sufficient to eliminate KA-induced WDS, and why the
action of anti-met5-enkephalin was most effective in reducing KA-
induced WDS in the ventral hippocampus.
In contrast to the effects on WDS, none of the wlchicine lesions
had effects on KA-induced behaviors such as facial and forelimb
clonus, rearing, and hypersalivation. These findings do not rule out
the possibility that enkephalin plays a role in hippocampal seizures,
but they do suggest that enkephalin released from mossy fibers is
not essential for seizure expression.
SUMMARY
The evidence accumulated so far indicates that seizure activity ex-
erts profound changes on the metabolism of opioid peptides in the
hippocampus. Our data consistently show a large transient decrease
in dynorphin and a modest decrease in enkephalin in the hippo-
campus following either a single ECS or KA injection. These initial
reductions, which are indicative of increased release, may trigger
the biosynthetic process of hippocampal opioids and result in an
overproduction of the peptides seen in the rebound phase. How-
ever, the amount and timing of the rebound in enkephalin and
dynorphin levels in response to repeated ECS, amygdaloid kindling,
or KA differ drastically: a rapid and sustained increase in ME-LI
follows all three treatments, in contrast to a slow recovery after a
large and sustained decrease in DN-Ll induced by repeated ECS and
amygdalold kindling. These results, which are unique to the hippo-
campus, suggest that differential mechanisms are operative in
regulating the metabolism of these two opioid peptides in the
hippocampus. lt is likely that a well-coordinated regulation of
hippocampal function can be achieved through the differential re-
lease of enkephalin and dynorphin and their subsequent interactions
at different subtypes of opioid receptors following seizure
activities.
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From a functional point of view, our data provide a neurochemical
correlate of previous reports that brain opioid peptides may mediate
ECS-induced behavioral alterations, such as changes in seizure
threshold, postictal depression, and retrograde amnesia. The robust
changes in the levels of opioid peptides in kindled rats, plus short-
ening of the kindling process by pretreatment with mu opioid
antagonists, strongly suggest the involvement of brain opioid pep
tides in the development of kindling. Finally, these studies show
clear evidence that enkephalin in the hippocampus is important in
KA-induced WDS, a component of the opiate withdrawal syndrome
in rodents (Isaacson and Lanthom 1981). Further studies should
help distinguish the regulatory mechanisms responsible for changes
in opioid peptide metabolism during states of hyperexcitability in
the hippocampai formation.
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Opioids in the Hippocampus:
Progress Obtained From In Vivo
Electrophysiological Analyses
Steven J. Henriksen, James B. Wiesner, and
Guy Chouvet
lNTRODUCTlON
The earliest evidence implicating a role for endogenous opioids in
hippocampal function derived from a survey of the actions of
electrophoretically applied opioid peptides on various central nerv-
ous system (CNS) structures (Nicoll et al. 1977). The unique excit-
atory actions of opioid peptides on the spontaneous discharge of
presumed hippocampal pyramidal neurons, when compared to inhibi-
tion of neuronal discharge observed for most other brain areas,
provided the impetus for an increasingly detailed analysis of the
actions of opioids in this structure (see Henderson (1983), Corrigall
(1983), and Siggins and Gruol (1986) for reviews). In parallel
studies, potential clinical relevance of hippocampal opioids was pro-
vided by a series of investigations conducted in unrestrained, freely
moving animals. Similar studies conducted in several laboratories
demonstrated that minute doses of intracerebroventricularly or
intracerebrally administered opioid peptides elicited nonconvulsive
epileptiform seizures in rats (Urca et al. 1977; Henriksen et al.
1978; Tortella et al. 1978; Elazar et al. 1979; Cain and Corcoran
1984). Significantly, these electrographic seizures were found to
have their origin in limbic structures, the major apparent focus
being the hippocampus (Henriksen et al. 1978; Henriksen et al.
1983b), and could be elicited with doses of opioids that were devoid
of analgesic or other overt behavioral signs (Henriksen et al. 1978;
Frenk 1983). In the past 5 years, with more precise localization of
hippocampal opioids and their receptor subtypes (McGinty, this
volume; Gall, this volume; Herkenham and McLean, this volume), a
systematic and more relevant functional analysis of hippocampal
opioids has been possible. The following essay will review the
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critical hippocampal studies employing in vivo methodologies and
will summarize the most recent evidence concerning the potential
roles opioids may play in hippocampal function and pathology.
ENCEPHALOGRAPHIC INVESTIGATIONS
As with the study of many other candidate neurotransmitters in the
CNS, electrophysiological observations of opioid effects on neurons
preceded precise immunohistochemical localization of hlppocampal
opioids and/or their receptors. Early studies employing intra-
cerebroventricular injections of the opioid peptides beta-endorphin
and leucine-enkephalin suggested a proconvulsant action for these
substances. Figure 1 illustrates an example of the onset of such an
event following beta-endorphin administration in a rat.
The multichannel encephalographic record shows the abrupt initia-
tion of high-voltage paroxysmal discharges recorded from numerous
sites. Systematic bipolar electrode recordings of subcortical brain
loci strongly suggested, however, that the hippocampus and amyg-
dala were the primary origins of this activity (Henriksen et al.
1978). Subsequent investigations using carbon-14-labelled 2-
deoxyglucose ([14C]2-DG) in conjunction with intracerebro-
ventricular beta-endorphin injections demonstrated conclusively that
the brain areas showing major increases in 2-DG uptake following
beta-endorphin coincided with the sites where the greatest
electrical abnormalities were recorded (figure 2).
In contrast, most other brain areas examined showed significant
decreases in 2-DG uptake during endorphin-induced seizures. These
early studies suggested that opioid peptides could produce patholog-
ical alterations in limbic neural activity and that the hippocampus
could play a major role in the elaboration of these epileptiform
events. ln an attempt to generalize these results to other species,
similar experiments employing a variety of other animals have been
conducted using beta-endorphin (Henriksen and Ehlers, unpublished
results). lntracerebroventricular injection of opioid peptides to
squirrel monkeys, cats, or rabbits have failed to evoke the type of
paroxysmal electrical discharge observed in rats (figure 3).
Although intermittent isolated high-voltage sharp waves were fre-
quently elicited, nothing akin to the frank ictal seizure episodes
were observed, even at dose levels producing behavioral analgesia
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FIGURE 1. Multitrace EEG record of beta-endorphin-induced
epileptiform activity in the rat
NOTE: Beta-endorphin was administered intracerebroventricularly in a total dose
of 3 nM at the end of the baseline trace. The top three traces are bi-
polar recordings of cortical EEG; the fast three traces are bipolar
recordings taken from deep electrodes in dorsal and ventral hippocampus.
and catatonia. In fact, in certain animal species exhibiting spon-
taneous or stimulus-induced seizures, opioid peptides and certain
opiate alkaloids have proved to be anticonvulsant (Meldrum et al.
1979; Bajorek and Lomax 1982). Moreover, more recent studies in
rat have demonstrated pro- as well as anticonvulsant properties of
opioid peptides depending on the seizure model employed and the
specificity of the ligand for particular opioid receptor subtypes
(Tortella et al. 1981; Tortella et al. 1985; Tortella et al. 1987;
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FIGURE 2. EEG traces and [14C]2-DG autoradiographic micrographs
of the response to intracerebroventricularly admin-
istered beta-endorphin (3 nM) in a representative rat
NOTE: (A) Electrographic tracing of ictal seizures episode elicited by beta-endorphin (B-
E). (B) [14C]2-DG autoradiographs of representative sections of control rat brain
and the brain of a rat exhibiting seizure shown in figure 2A following B-E.
Henriksen et al. 1978; Snead and Beardon 1980; Frenk 1983). The
role of hippocampal opioids in seizure activity has been further
complicated by the observation that spontaneous and artificially
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FIGURE 3. lntracerebroventricular beta-endorphin in the squirrel
monkey
NOTE: EEG traces recorded from cortical and subcortical sites following the
administration of 200 µg of beta-endorphin intracerebroventricularly.
Note high-voltage slow cortical EEG associated with fast hippocampal
rhythms.
induced seizure episodes in experimental animals are associated with
changes in the postseizure content of opioids in this structure
(Hong et al. 1980; McGinty et al. 1983; Hong et al., this volume;
Gall, this volume). Finally, postictal behavioral as well as electro-
graphic activity in several seizure models have been shown to be
sensitive to naloxone, indicating that endogenous opioids potentially
released during seizures may serve to decrease the probability of
subsequent seizures and the aberrant postictal and/or interictal
behaviors (Frenk et al. 1979; Caldecott-Hazard et al. 1984; Bajorek
et al. 1986).
To summarize, a decade of data obtained using electroencephalo-
graphic tools has suggested a multitude of intriguing relationships.
First, it appears that ventricularly administered opioids can produce
naloxone-reversible synchronized epileptiform events in rat hippo-
campi, and at least some paroxysmal activity in other species as
well. This indicates that opioids can act at receptors in the
hippocampus to facilitate specific patterns of excitation/inhibition
at the cellular level which result in the complex EEG waveforms
described above. Second, hippocampal opioids may also function to
71
attenuate and/or block the recurrence of ictal episodes by causing
a selective depression of cellular excitability. Last, the specific
opioid receptor subtypes, the specific distribution of endogenous
opioid ligands, and the localization of opioids within the intrinsic
circuitry of the various subfields of the hippocampal formation may
be the critical factors underlying the observed EEG actions of opi-
oids and their antagonists.
CELLULAR lNVESTIGATlONS
Early in vivo extracellular studies of opioid effects on hippocampal
neurons were consistent with the EEG studies described above.
That is, electrophoretic application of endorphin peptides elicited
increases in spontaneous discharge of isolated hippocampal neurons
in contrast to the decreases in activity observed in other brain
areas (Hill et al. 1977; Nicoll et al. 1977; Zieglgänsberger et al.
1979). In addition, prolonged ejection of beta-endorphin from adja-
cent micropipettes elicited paroxysmal unfiltered potentials that
FIGURE 4. Effects of electrophoretically applied beta-endorphin on
hippocampal CA 1 neuron discharge and local EEG
NOTE: Upper trace: DC unfiltered recording (low gain) from microelectrode tip.
Beta-endorphin (150 nA) ejected during DC deflections. (Note sharp
waves emerging following beta-endorphin application.) Bottom trace:
Ratemeter record of individual CA1 neuron. (Note increase in spontane-
ous rate associated with beta-endorphin application.)
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were synchronous with EEG-recorded epileptifom activity (French
and Siggins 1980) (figure 4). These data provided the first cellular
evidence substantiating the excitatory action of opioids on hippo-
campal neurons and demonstrated that this global effect could
occur as a direct result of the local application of opioid peptide,
rather than being mediated indirectly through distant, extra-
hippocampal processes.
These cellular electrophysiological findings were made in the ab-
sence of firm evidence of either a significant concentration of opi-
ate receptors (identified by the use of tritiated naloxone), or of
substantial amounts of opioid peptide in the hippocampus. However,
with the demonstration first of enkephalin-like immunoreactivity in
the hippocampus (Gall et al. 1981) and, later, of dynorphin-like
immunoreactivity (McGinty et al. 1983; McGinty 1985), with a clear
difference in the distribution of these two peptides in the hippo-
campus, an impetus was provided to investigate the potential roles
of the endogenous opioids in those hippocampal areas of preferred
opioid distribution (Gall, this volume; McGinty, this volume).
Early immunohlstochemical investigations of endogenous oploids in
rodents demonstrated broad distribution in most limbic structures
but sparse labelling of cells in the hippocampus (Sar et al. 1978;
Bloom and McGinty 1981). More recent radioimmunoassay studies,
however, have revealed a significant concentration of leu5-
enkephalin (ENK)-immunoreactivity (IR) in the dentate-CA3 fields
with only half as much ENK-IR in CA1 and the subiculum (Bayon et
al. 1983).
The mossy fiber pathway originating in dentate granule cells and
projecting through the hilus to innervate CA3 pyramidal cell den-
drites was originally thought also to contain primarily enkephalin
(Gall et al. 1981). The enkephalin antisera used in these earlier
immunochemical studies, however, also cross-reacted with dynotphin.
Subsequent histochemical studies using more specific antisera
(McGinty et al. 1983) have shown that mossy fibers primarily pos-
sess immunoreactivity for dynorphin(s) and a much lower level of
proenkephalin-derived opioids (Khachaturian et al. 1983; McGinty
et al. 1984, White et al. 1987). This pathway was previously
thought to be exclusively excitatory, releasing an acidic amino acid
such as glutamate or aspartate. The presence of prodynorphin-
derived peptides and an excitatory amino acid in the same pathway
has aroused speculation that these substances, and perhaps others
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(Gall, this volume), may be cotransmitters within the same mossy
fiber terminals.
In addition, more recent hlstochemical studies of the rat CA1
hippocampal field demonstrate scattered dynorphin-IR and
enkephalin-IR cells and fibers (Bayon et al. 1983; Gall et al. 1981;
McGinty et al. 1984). Enkephalin-IR and proenkephalin-IR (but not
dynorphin-IR) are also observed in the rat entorhinal cortex in
cells that project to the hippocampus and dentate gyrus (McGinty
1985). Thus, opioid immunoreactivity in the three opioid peptider-
gic systems of the hippocampal formation represents the presence
of three different prohormonal systems: (1) predominantly pro-
dynorphin-derived peptides in the dentate-CA3 mossy fiber pathway;
(2) predominantly proenkephalinderlved peptides in scattered inter-
neurons in CA1 and CA3; and (3) proenkephalinderived peptides in
the entorhinal to dentate gyrus perforant pathways.
The localization of the opioid peptides in nerve cells and fibers of
the hippocampus suggest that they are likely transmitter candidates.
This possibility is supported by recent biochemical studies showing
that at least five related prodynorphin/neoendorphin derived pep-
tides can be released from hippocampal slices by high K+ in a
Ca2+dependent manner (Chavkin et al. 1983a). These include
dynorphin A(1-17), dynorphin A(1-8), dynorphin B, alpha-
neoendorphin, and beta-neoendorphin. Proenkephalin derived
peptides are also released in this preparation (Chavkin et al. 1983a;
Chavkin et al. 1983b). In light of acknowledged distributional
differences in endogenous hippocampal opioids, it is of heuristic
value to discuss separately the three major hippocampal cellular
fields-CA1, CA3, and dentate gyrus-and their respective responses
to exogenously applied opioids.
NEUROPHARMACOLOGY OF OPIODS IN AREA CA1
Due primarily to their dorsal location in the hippocampal formation
and resultant ease in isolation and recording stability, cells in the
CA1 field were early targets for analysis of opioid effects. In
CA1, enkephalin immunoreactlvity is distributed as a band of re-
active vaticosities within the border of the stratum radiatum and
stratum lacunosum-moleculare.
When opioids, including the enkephalins beta-endorphin and dynor-
phin A, are ejected from micropipettes in the vicinity of CA1
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pyramidal neurons in vivo, the consensus effect is to increase the
spontaneous discharge of these cells (see Henderson (1988) and
Siggins and Gruol (1986) for reviews). These effects are naloxone
reversible and therefore presumed to be mediated by opiold recep-
tors. As previously demonstrated (see figure 4), large lontophoretic
currents of beta-endorphin during single-unit recording of CA1
neurons can trigger repetitive large DC potentials suggestive of
epileptiform activity (French and Siggins 1980). The single-unit
excitation and epileptiform activity are intrinsic to the hippo-
campus, since they can also be evoked by superfusion of opioids
into intraocular transplants of hippocampus (Taylor et al. 1979).
Considerable effort has been expended to analyze and comprehend
the mechanisms underlying the paradoxical excitatory effects of
opioids on hippocampal neurons (see Siggins and Gruol (1988) for a
review). In vivo studies of hippocampal neurons using gamma-
aminobutyric acid (GABA) blockade by bicuculline and blockade of
transmitter release by Mg2+ ions indicate that the excitatory
FIGURE 5. A model for opioid disinhibition
NOTE: Left panel: Poststimulus histograms before and during electrophoretic
application of met-5-enkephalin on a CA1 neuron. During control, anti-
dromic activation is followed by a prolonged inhibitory sequence. This
inhibition (mediated by GABA interneurons) is blocked by met-5-
enkephalin electrophoresis. Right panel: Proposed model of disinhibition
(see text).
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responses of hippocampal CA1 pyramidal neurons may be viewed as
indirect, resulting from a primary inhibitory effect of the opioid on
neighboring inhibitory interneurons, leading to excitation of pyram-
idal cells by dlsinhibitlon (Zieglgänsberger et al. 1979; Lee et al.
1980). Figure 5 illustrates the proposed model for this interaction.
Despite this evidence, extracellular studies cannot reveal the exact
mechanisms behind this unique opioid excitation. Several laborato-
ries have therefore conducted intracellular studies using in vitro
preparations such as hippocampal slices or explant cultures.
Such intracellular studies of pyramidal cells of the hippocampus
CA1 have shown little or no direct effects on membrane potential
or input resistance of morphine or several opioid peptides (leu5-
enkephalin; met-5-enkephalin; D-ala2,D-leu5 enkephalin; D-ala2,D-
leu5-enkephalin amide; beta-endorphin) in concentrations up to
50 µM (Dingledlne 1981; Gahwiler and Herding 1981; Gruol et al.
1988; Haas and Ryall 1980). The lack of a direct membrane effect
on pyramidal cells is predicted by the disinhibition hypothesis.
Unfortunately, there has not been complete agreement as to the
mechanism by which the opioids alter synaptic potentials. Intra-
cellularly, most studies on the hippocampal slice indicate that the
enkephalins and beta-endorphin primarily reduce the size of pre-
sumed GABAergic recurrent and feedforward inhibitory postsynaptic
potentials (IPSPs) in both the CA1 and CA3 fields, and perhaps in
the dentate gyrus as well (Gruol et al. 1988; Masukawa and Prince
1982; Nicoll et al. 1980; Siggins and Zieglgänsberger 1981). This
also supports the hypothesis of a disinhibltory mechanism. Dis-
inhibltion appears to be exerted presynaptically to the pyramidal
cell since pyramidal cell responses to GABA, the likely transmitter
for these IPSPs, are not reduced by the opioids (Dingledine 1981;
Nicoll 1982).
However, in other hippocampal slice studies (Dingledine 1981; Haas
and Ryall 1980), only enhanced excitatory postsynaptic potentials
(EPSPs) or, conversely, a reduction of EPSPs (as well as IPSPs and
depolarizing glutamate responses) were observed in about one-half
of the pyramidal neurons studied (Siggins and Zieglgänsberger 1981).
lt is still uncertain whether the observed hippocampal opioid effects
are due to direct hyperpolarization of interneurons, to a true
modulation of transmitter release, or to a more remote action.
However, the bulk of the extracellular data (Dunwiddie et al. 1980;
Lee et al. 1980; Nicoll 1982; Zieglgänsberger et al. 1979) and
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intracellular data (see Robinson and Deadwyler (I 981) and text
above) still support a disinhibitory mechanism of action for the
single-unit excitatory and epileptigenic effect of these opioid
peptides in the hippocampus (see Corrigall (1983) for a review).
Still, facilitation of excitatory transmission has not been ruled out
entirely. Some discrepancies between laboratories might be ascribed
to (1) different methods of afferent stimulation in vitro and diffi-
culties in selectively stimulating pure excitatory or inhibitory
pathways; (2) the use of different opioid agonists acting on differ-
ent opiate receptors; (3) the method of drug administration; and/or
(4) the fact that the hippocampal pyramidal cell is usually the
subject of these intracellular recordings, while the primary site of
opioid action appears to be presynaptic to this cell. However, a
preliminary intracellular study by Nicoll and Madison (1984) demon-
strated that enkephalin analogues hyperpolarize hippocampal inter-
neurons by increasing their potassium conductance, thus directly
supporting the disinhibiiion hypothesis. in another recent in vitro
extracellular investigation, Raggenbass et al. (1985) studied the
action of a variety of opioids selective for certain opioid receptor
subtypes on nonpyramidal neurons in the CA1 region. These
authors found that the mu-selective agonist [D-Ala2-MePhe4-Gly-
ol5-enkephalin (DAGO), but not the kappa-selective agonist
U50,488H, decreased the spontaneous discharge of presumed inhibi-
tory interneurons in a naloxone-reversible fashion. These cellular
data support earlier field-potential studies (see below) suggesting
that the indirect, excitatory action of opioids in all hippocampal
cell fields studied may be mediated by a mu- and perhaps a delta-
opioid receptor (Chavkin et al. 1985; Chavkin et al., this
.
Another important electrophysiological tool used successfully to
assess the effects of opioids in the hippocampus is the measurement
of cellular excitability following afferent pathway stimulation. Be-
cause of the precise laminar arrangement of neurons, dendrites,
and axons in the hippocampus, large synaptic potentials can be re-
corded with electrodes situated in selected strata of the hippo-
campal formation. These potentials are believed to represent local
synchronous synaptic input evoked by afferent stimulation
(Anderson et al. 1971). Although few studies have investigated the
effects of opioids on these stimulated potentials in vivo, the exist-
ing data support the proposition that opioids elicit disinhibitory
effects when tested in this assay system. Early studies by
Linseman and Corrigall (1982) demonstrated that systemic morphine
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potentiated the population field potentials evoked by stimulation of
the afferent pathways to both CA1 and the dentate gyrus in the
freely moving rat. Dunwiddie et al. (1980) described similar results
for d-met-5-enkephalin amide in the CA1 region in urethane-
anesthetized rats and, further, demonstrated that the action of the
opioid could be mimicked by the GABA antagonist picrotoxin. In
addition to the in vivo studies described above, numerous in vitro
investigations have examined the effects of opioids in the CA1 area
of the hippocampal slice preparation (Dingledine 1981; Dunwiddie et
al. 1980; Gawiler and Herding 1981; Gruol et al. 1983; Haas and
Ryall 1980; Masukawa and Prince 1982; Nicoll et al. 1980; Roblnson
and Deadwyler 1981; Siggins and Zieglgänsberger 1981; and many
more). In reviewing these data, two flndings emerge as wmmon
denominators. First, superfusion or local application of opioid
peptides increases the excitability of neurons in CA1 as documented
by an increase in the evoked population spike and field EPSP.
Second, opioids frequently give rise to multiple afterpotentials,
which follow the primary population spike and are likely to be the
result of the opioid-mediated decrease in recurrent inhibition (see
Corrigall (1985) for a review).
In an attempt to define more precisely the opioid receptor type
mediating these effects on evoked field potentials, two pharmaco-
logical strategies have been employed. First, several investigators
have used highly selective opioid receptor agonists to determine the
specificity of opioid action in the hippocampus (Iwama et al. 1986;
Vidal et al. 1984; Wiesner and Henriksen 1987a; Raggenbass et al.
1985; Chavkin et al., this volume). Second, Chavkin et al. (1985)
employed selective receptor inactivation in conjunction with selec-
tive opioid agonists to further characterize the opioid receptor sub
types mediating the alteration in cellular excitability. Roth lines of
investigation have revealed that, throughout the hippocampus, the
opioid-induced increase in cellular responsiveness is mediated by
both mu and delta opioid receptors. The kappa-selective opiates
U50,488H and ethylketocyclazocine are inactive when tested in
physiologically meaningful dose ranges (Chavkin et al., this volume).
In summary, the findings from in vivo investigations of opioid
neuropharmacology in the CA1 region of the hippocampus are con-
sistent with the pharmacological actions of opioids observed in both
freely moving animals and in vitro preparations. These effects are
also consistent (Dingledine 1981) with the observed anatomical dis-
tribution of opioids in this hippocampal subfield (Gall, this volume;
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McGinty, this volume) as well as the regional distributions of opioid
receptor subtypes as assessed by ligand-binding studies (Herkenkam
and McLean, this volume). The main effect of exogenously applied
opioids is to decrease tonic and recurrent inhibitory processes in
presumed GABAergic interneurons, leading to an increase in sponta-
neous discharge rate of individual CA1 pyramidal neurons and an
increase in neuronal excitability assessed by afferent stimulation.
Despite the relative unanimity regarding the major pharmacologic
actions of opioids in CA1, other questions regarding the role of
opioids in hippocampal function remain: (I) There is no known
neurophysiological event altered by the systemic or local adminis-
tration of the opioid antagonist naloxone (but see Gallagher (this
volume)); (2) controversy still attends the explanation of the cellu-
lar mechanism underlying disinhibition in CAI; and (3) substantial
quantitative differences are seen in opioid-induced effects from in
vivo compared to the in vitro preparation. These unresolved
issues, not discussed in detail here, suggest that the hippocampal
slice preparation may have severely compromised intrinsic inhibitory
processes that may in turn taint opioid responsiveness (Dunwiddie
et al. 1980; lwama et al. 1986; Durand et al. 1981), and/or anesthet-
ics employed by neuropharmacologists in vivo may alter opioid
neuropharmacology or cellular responsiveness.
NEUROPHARMACOLOGY OF OPIOIDS IN AREA CA3
Far fewer studies of opioids in the hippocampus have been directed
toward pyramidal cells in subfield CA3. CA3 neurons, however,
provide a unique assay for opioid function in the hippocampus be-
cause, in addition to scattered enkephalinergic terminal and cell
bodies located in the zone stratum radiatum, CA3 neurons receive a
massive projection of prodynorphinderived peptides carried by the
mossy fibers of the dentate granule cells (Gall et al. 1981; McGinty
et al. 1983; Gall, this volume; McGinty, this volume). CA3 neurons
therefore have the potential for being acted upon by endogenous
opioids indirectly through the mechanism described for subfield
CA1 , as well as directly through prodynorphinderived peptides re-
leased from the mossy fiber terminals. Results from in vivo studies
of CA3 neuron responsiveness to exogenously applied opioids reflect
these complexities. Met-5-enkephalin and its stable analogues uni-
formly increased the spontaneous discharge of CA3 neurons in in
vivo electrophoretic experiments (Henriksen et al. 1982a; Henriksen
et al. 1983a; Moises and Walker 1985). These effects were naloxone
reversible and similar to the responses seen for cells in the CA1
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region of the hippocampus. They likely reflect the same dis-
inhibitory processes proposed for those neurons (see above). In
contrast, prodynorphinderived opioids have less consistent effects
when applied to CA3 neurons in vivo. Henriksen et al. investigated
the effects of several prodynorphin-derived peptides (dynor-
phin A(1-17), dynorphin B, alpha-neoendorphin, dynorphin A(1-8),
and des-tyr-dynorphin A(2-17)) on spontaneous discharge of CA3
neurons as well as on cellular excitability (Henriksen et al. 1982a;
Henriksen et al. 1983a; Henriksen et al. 1983b). We observed that,
in halothane-anesthetized rats, dynorphin A(1-17), dynorphin A(1-8),
and dynorphin B, but not dynorphin A(2-17), had predominantly
excitatory (77 percent) effects on CA3 neurons. These effects were
naloxone reversible.
Figure 6 illustrates the prolonged excitatory effect of electro-
phoretically applied prodynorphin products on a CA3 neuron. Given
the results obtained in CA1, where mu agonist activity for dynor-
phin A(1-17) has been observed in vitro (Chavkin et al. 1985), and
the fact that the effect in CA3 can be blocked by the synaptic
uncoupling agent magnesium, the excitatory effects of dynotphin on
CA3 neurons probably reflects a disinhibiiory action of the peptide
similar to that observed for enkephalin in both cell fields. How-
ever, variable percentages of CA3 neurons respond to dynorphin
(and other kappa-receptor-selective opiates) with a decrease in
FIGURE 6. Excitatory effects of prodynorphin-derived peptides on
a CA3 neuron
NOTE: Electrophoretic application of dynorphin A(1-17), alpha-neoendorphin. and
dynorphin A(1-8). Note apparent relative potencies.
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spontaneous discharge (Brookes and Bradley 1984, Moises and
Walker 1985; Henriksen et al. 1982a; Henrlksen et al. 1983b).
Figure 7 is an example of dynotphin- and ethylketocyclazocine (Win
38-197)-induced inhibltion of a CA3 neuron with partial naloxone
reversal. lt appears therefore that the direct effect of dynorphin
on CA3 neurons may be inhibitory, consonant with the direct
actions of opioid peptides in many other brain areas. Moreover,
the more selective the drug is for kappa opioid receptors, the
higher the percentage of inhibition of CA3 neuron one obtains,
suggesting that the observed inhibitory effects may be mediated by
kappa receptors. Figure 8 is an example of inhibition of a CA3
neuron elicited by the highly selective kappa ligand, U50,488H.
FIGURE 7. Inhibitory response to dynorphin
NOTE: Top: Ratemeter records from a CA3 hippocampal neuron during electro-
phoretk administration of dynorphin (dyn A(1-17)) and ethylketo-
cyclazocine (Win 35-197). Bottom: Naloxone antagonism of dynorphin-
induced inhibition. Note that, even with low ejection current (5 nA) of
naloxone, there is a substantial decrease in the apontaneous firing rate,
between the ejectlng pulses, underlying a possible nonspecific effect for
naloxone.
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FIGURE 8. Ratemeter record of a CA3 neuron during iontophoretic
applications of kappa agonist U50,488H
NOTE: Note the somewhat higher than usual spontaneous firing rate, whkh
permits observation of U50,488H Inhibition.
SOURCE: Siggins et al. 1986, Copyright 1982, Raven Press.
Preliminary intracellular studies of dynorphin effects on CA3
pyramidal neurons in the hippocampal slice are relatively consistent
with these extracellular findings: depending on the particular cell
study, either slow hyperpolarizing or depolarizing responses are
seen with low concentrations of dynorphin A and dynorphin B
(Gruol et al. 1983). The changes in membrane potential were occa-
sionally associated with changes in discharge activii in a direction
opposite to that expected (Gruol et al. 1983), thus raising the
possibility of an indirect action of dynorphin. The depolarizing
responses were also not of the type expected of mossy fiber activa-
tion, being slow and not always capable of activating spikes. Simi-
lar mixed or weak effects in CA3 were seen in vitro with respect
to the action of dynorphins on extracellular field potentials evoked
by mossy fiber stimulation, although inhibitory action was some-
times observed (also see lwama et al. (1986)).
Preliminary studies in our laboratory on the effect of locally
applied dynorphin A(1-17) or naloxone on mossy fiber evoked field
potentials in vivo have yielded other intriguing results. Using pairs
of stimulus pulses to assess the action of opioids on sequential
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recurrent inhibition and/or potentials, we have observed that
neither dynorphin nor naloxone has effects on either the primary
or secondary evoked population spike. The second evoked response,
however, is followed occasionally by an afterpotential. This after-
potential is potentiated by electrophoretically applied dynorphin
A(1-17) and inhibited by electrophoretically applied naloxone (see
figure 9).
These results imply that an opioid peptide released by mossy fiber
stimulation, although not altering the primary excitatory effects on
CA3 neurons, may serve as a modulatory agent enhancing s&se-
quent inputs to the CA3 area in a frequency-dependent fashion.
FIGURE 9. Effect of iontophoretically applied naloxone on CA3
field potentials evoked by mossy fiber stimulation
NOTE: Field potentials in (A) represent CA3 overlaid double pulse stimulation
responses (interstimulus interval was 185 msec). Note emergence of
potential at approximately 8 msec during second stimulus. In (B), note
decrease In this potential. In (C), recovery follows naloxone
electrophoresis. Response is plotted at left and represents the mean of
10 responses at each point.
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NEUROPHARMACOLOGY OF OPIODS IN THE DENTATE GYRUS
As demonstrated by immunocytochemical studies (Gall et al. 1981;
McGinty et al. 1983), the fascia dentata of the hippocampus con-
tains endogenous opioid peptides from various anatomical sources.
Three known sources of opioids observred in the dentate gyrus are
(1) an enkephalinergic pathway arising from the entorhinal cortex;
(2) intrinsic enkephalinergic local circuit neurons; and (3) the
dentate granule cells themselves, which contain predynorphin-
derived peptides (Christian et al. 1985; Linseman and Corrigall 1982;
Wiesner et al. 1988; Wiesner and Henriksen 1987a; Wiesner and
Henriksen 1987b). The few studies that have examined the
physiological effects of opioids in the dentate gyrus in vitro (Haas
and Ryall 1988; Tielen et al. 1981) or in vivo have focused on field
potentials evoked by stimulation of the afferent perforant path.
These studies have generally found exogenously applied opioids to
exert an “excitatory” effect in that the opioids enhanced evoked
potentials, indicating an increased response of the granule cells to
input from the perforant path. In this respect, the effect of opi-
oids in the dentate gyrus appears to be similar to the effect of
opioids in the hippocampal subfields CA1 and CA3, where evoked
potentials are also enhanced (Corrigall 1983). This parallelism of
pharmacological effect is reinforced by the finding that, in a
fashion similar to that previously discussed for CA1 and CA3, opi-
oids applied to the dentate gyrus decrease sequential inhibition as
determined by a “paired-pulse” paradigm (Wiesner et al. 1988).
While a disinhibftory action of opioids like that seen in the CA1
and CA3 subfields might be expected in the dentate gyrus, similar
effects of opioids on individual dentate granule cells have only
been recently reported (Wiesner et al. 1986; Wiesner and Henriksen
1987b; Chavkin et al., this volume). Using a prototypic opioid ago-
nist (D-ala2-met-5-enkephalin amide (DAMEA)), we have assessed
the effects of electrophoretic application on granule cell spontane-
ous discharge and responsivity to afferent input. Although
DAMEA has been used as a standard opioid agonist in other stud-
ies, we have determined that selective mu agonists, but not delta
or kappa agonists, produce comparable results (Wiesner and
Henriksen 1987a) (but see Chavkin et al. (this volume)).
To evaluate recurrent (or feedforward) inhibition characteristics of
hippocampal circuitry, a paired-pulse paradigm was employed before
and during each opioid application. This paradigm involved pairs of
stimulus pulses (a “conditioning” pulse followed by a “test” pulse)
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with varying interpulse intervals. Under control conditions, the
test response is normally inhibited at short interpulse intervals
(less than 50 msec) but facilitated at longer interpulse intervals (50
to 140 msec). During the DAMEA application, the inhibition char-
acteristic of short interpulse intervals was decreased, resulting in
significantly greater test responses at 20- and 40-msec interpulse
intervals. The decreased inhibition in the presence of opioids re-
sembles that which is induced by certain other opioid peptides
(Wiesner and Henriksen 1987a) and is reversed by naloxone.
Recordings of single units within the granule cell layer allowed
testing of their response to opioid peptides. Electrophoretic appli-
cation of DAMEA consistently inhibited the spontaneous activity of
dentate units while concurrently increasing the amplitude of evoked
population spikes (figure 10). When unit responses to perforant
path stimulation could be identified superimposed on the field
potentials (5 to 15 msec poststimulus), an increased number of
evoked action potentials was seen during DAMEA application, sug-
gesting that evoked unit activity was increased even though spon-
taneous cellular activity was suppressed.
The inhibition of spontaneous unit activity (and the concurrent
increase in population spike amplitude) by DAMEA was antagonized
by naloxone. The results of this study again confirm that exoge-
nously applied opioids can enhance the excitatory response of the
dentate gyrus to perforant path stimulation, and that this effect is
associated with a disinhibition of the evoked response as deter-
mined by paired-pulse stimulation. In addition, the results have
demonstrated a concurrent inhibition of spontaneous granule cell
activity by an enkephalin analogue. Although this inhibitory effect
of enkephalin is typical of that seen in most areas of the brain
(North 1979), it is surprising in light of the opioid effects reported
in other hippocampal areas and presents an interesting paradox with
respect to the “excitatory” effect of enkephalin on responsiveness
to perforant path stimulation. It is possible that these divergent
opioid effects may be causally related, although it seems likely that
the effects may be mediated through separate mechanisms. While
these mechanisms remain obscure, the enhanced response to perfo-
rant path input may result from a disinhibitory effect of opioids;
this effect could be opposed by a separate, perhaps more direct
inhibitory opioid effect. Alternatively, it is conceivable that the
decreased spontaneous firing rate may predispose the cell to an
increased synchrony of response to incoming stimuli.
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FIGURE 10. Concurrent effects of DAMEA on population spike
amplitude (PS amp) and on spontaneous tiring rate of
a single unit of the granule cell layer
SOURCE: Wiesner and Henriksen 1987a, Copyright 1987, Elsevier Ltd.
These results underscore the importance of caution in interpreting
effects of drugs as “excitatory” or “inhibitory” based on studies of
evoked potentials alone. Evoked activity such as that reflected by
dentate field potentials must be considered a specific measure of
transmission within the individual neural pathway involved.
CONCLUSION
lt is clear from the foregoing review of in vivo opioid neuro-
pharmacology that opiold peptides exist in the hippocampus and
can dramatically influence neuronal excitability. The question still
remains as to what degree endogenous opioids are functionally in-
volved in hippocampal physiology. However, in light of the data
described, the presence of multiple opiate receptors differentially
distributed in the hippocampus could explain the complex cellular
and EEG effects of the various opioid peptides. These multiple
receptors and their distributions could therefore clarify a possible
role of opioid peptides in normal hippocampal cellular activity as
well as in limbic epilepsy and drug abuse. Hence, opioid peptides
of the beta-endorphin-enkephalin class and morphine-like opiate
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alkaloids, which act with some degree of selectivity on mu and del-
ta receptors, appear to be predominantly excitatory in the hippo-
campus. The dynorphins exhibit both excitatory and inhibitory
effects, perhaps via actions at both mu and kappa receptors. lt
seems likely that the predominant receptors involved in opioid ef-
fects in the CA1 cell field of the hippocampus and the dentate
gyrus are of the mu and delta subtypes, whereas kappa receptors
also may be involved in CA3 opioid response. lt seems apparent
that a multidisciplinary approach will continue to be required be-
fore the potential roles of the hippocampal opioids will be finally
characterized.
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Opioid Receptor Mechanisms in the
Rat Hippocampus
Charles Chavkin, John F. Neumaier, and
Elizabeth Swearengen
INTRODUCTION
When the actions of opiates were measured on individual neurons,
the predominant effects seen throughout the nervous system were
membrane hyperpolarization and decrease in firing rate (Nicoll et
al. 1977; Duggan and North 1984; Henderson 1983). An opioid-
induced increase in excitability shown by hippocampal CA1 pyram-
idal cells was therefore viewed as an anomaly. The ionic basis for
opioid actions outside the hippocampus has been shown to be an
increase in membrane conductance to potassium following activation
of mu or delta opioid receptors, or alternatively, a decrease in a
voltage-dependent calcium conductance following activation of
kappa opioid receptors. Investigation of the response to opioids
within the CA1 region of the hippocampus revealed that the direct
action of opioids was also an increase in potassium conductance
(North 1986). To account for opioid-Induced excitation in the
hippocampus, several groups have proposed that opioids hyper-
polarize a population of interneurons and thereby inhibit the
release of an inhibitory transmitter that normally controls the
excitability of the CA1 pyramidal cells (Henderson 1983). In this
article, we review some Of the recent evidence supporting this
hypothesis and present data suggesting that opioids act via a
similar cellular mechanism in the dentate and CA3 regions of the
hippocampus.
IONIC BASIS OF OPIOID ACTlON
Wen and Macdonald characterized the opioid receptors and ionic
transduction mechanisms involved in mediating the actions of
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opioids by studying the electrophysiological effects of opioids
applied to fetal mouse dorsal root ganglion (DRG) cells in culture
(Wen and Macdonald 1983; Wen and Macdonald 1984; Macdonald
and Wen 1986). In this preparation, opioids decrease calcium-
dependent action potential duration (Werz and Macdonald 1983), as
was reported previously for cultured chick DRG cells (Mudge et al.
1979). In addition, kappa-specific opioids also selectively reduced
the voltage-sensitive calcium conductance (Werz and Macdonald
1984; Werz and Macdonald 1985); however, the mechanism of action
for kappa receptors was different from that for mu or delta recep-
tors. Intracellular recordings showed that electrodes filled with
cesium acetate (blocking potassium conductances) completely inhib-
ited the effects of [Leu5]enkephalin (delta agonist) and morphicep-
tin (mu agonist), whereas cesium did not affect the reduction in
calcium conductance caused by dynorphin-A(1-17), dynorphin-
A(1-8), dynorphins, and alpha-neoendorphin (kappa agonists). The
authors therefore concluded that kappa receptors primarily control
a calcium channel in mouse DRG cells, whereas delta or mu recep-
tor activation decreases calcium conductance by directly increasing
potassium conductance (Werz and Macdonald 1984; Wen and
Macdonald 1985).
Opioid receptor-linked conductance changes were also measured in
guinea pig myenteric neurons. Neurons in the myenteric ganglia
respond to application of mu-selective opioids with a 3-to 7-mV
hyperpolarization accompanied by a decrease in membrane resistance
(Morita and North 1982). Opioids also prolong the calcium-
dependent hyperpolarization that normally follows a burst of action
potentials (IK(Ca)) (Tokimasa et al. 1981). These effects were
shown to be mediated by mu receptor activation by the sensitivity
of a variety of opioids to antagonism by beta-funaltrexamine
(beta-FNA) (Cherubini and North 1985), a mu-receptor-alkylating
agent (Portoghese et al. 1980; Takemori et al. 1981). Several
observations demonstrated that the ionic basis of the hyper-
polarization is an opioid-induced increase in potassium conductance:
(1) the amplitude of the hyperpolarization depends on the external
potassium concentration: (2) the reversal potential of the opioid-
activated current is about -100 mV, a value close to the potassium
equilibrium potential of these cells (Morita and North 1982;
Tokimasa et al. 1981); and (3) potassium channel blockade by
intracellular cesium injection blocks the mu receptor-mediated
hyperpolarization (Cherubini and North 1985).
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Kappa agonists (e.g., dynorphin-A(1-17), tifluadom, and U50,488H)
affect guinea pig myenteric neurons differently than delta and mu
agonists. Rather than membrane hyperpolarization, cells respond
with a reduction in the duration of the calcium-dependent action
potential (Cherubini and North 1985). Kappa agonist action is
distinguishable from mu receptor activation in the same preparation
by the insensitivity of kappa agonists to beta-FNA treatment, and
by either the intracellular injection of cesium or the addition of
low concentrations of barium to the super-fusion buffer to block
potassium channels (Cherubini and North 1985; Cherubini et al.
1985). The results of experiments using these techniques suggest
that kappa receptors are present on myenteric neurons and are
coupled to calcium channels. Thus, kappa and mu receptors in this
tissue, as in mouse DRG neurons, are apparently linked to different
transduction mechanisms, although both may reduce calcium influx
during the action potential.
Analysis of opioid effects on locus coeruleus neurons in rat brain
slices demonstrates that mu receptor activation causes a membrane
hyperpolariration of these neurons as well (Pepper and Henderson
1980; Williams et al. 1982; Williams et al. 1984). Experimental
manipulations similar to those done for the guinea pig myenteric
neurons show that the membrane hyperpolarization is due to an
increase in potassium conductance. In addition, quinine (200 µM),
which blocks specific potassium channels in vertebrate and in-
vertebrate neurons (Walden and Speckmann 1981; Yoshida et al.
1986), also blocks the opioid-activated potassium conductance in
locus coeruleus neurons (North and Williams 1985). These data
indicate that mu opioid receptors are linked to similar transduction
mechanisms not only in different tissues but in different species as
well.
Delta receptors have been characterized in neurons of the sub-
mucous plexus of the guinea pig ileum. These neurons were hyper-
polarized following application of delta agonists, [Met5]enkephalin,
[Leu5]enkephalin, [D-Ser2,L-Leu5,L-Thr6]enkephalin (DSLET), or
[D-Ala2,D-Leu5]enkephalin (DADLE) (Surprenant and North 1985;
Mihara and North 1986). Opioid effects on the submucous plexus
neurons were found to be mediated by delta receptors as shown by
the apparent dissociation constants of naloxone and ICI-l 74864 cal-
culated by Schild analysis (Schild 1947; Schild 1949) and by the
insensitivity of the cells to either mu or kappa agonists. The con-
ductance change was very similar to that controlled by mu receptor
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activation in the myenteric plexus (i.e., hyperpolarization that
reversed at the potassium equilibrium potential and appeared to
result from an outward potassium current).
Based on studies of the submucous plexus in vitro and of DRG cells
in culture, the properties of the delta-receptor-activated potassium
channel were indistinguishable from the mu receptor channel. The
similarity In mechanism may reflect a close evolutionary relation-
ship between the mu and delta receptors and suggests that there
may be other common features. In contrast, kappa receptors have
been shown to control calcium conductance. However, the net ef-
fect on cell excitability may be the same regardless of which
mechanism is activated. Increased potassium conductance reduces
excitability of the postsynaptic cell and decreases transmitter re-
lease at the nerve terminal. lnhibition of calcium conductance
also reduces postsynaptic cell excitability by reducing the calcium
component of the action potential. Reduction of transmitter release
may result if kappa receptors are also located on the nerve
terminals.
ENDOGENOUS OPIOlD IN THE HIPPOCAMPUS
Interest in the actions of opioids in the CA3 region of the hippo-
campus was greatly stimulated by the immunocytochemical localiza-
tion of proenkephalin- and prodynorphinderived opioids in the
dentate gyrus and mossy fiber pathway of the rat hippocampus (Gall
et al. 1981; Gall 1984; McGinty et al. 1983; McGinty et al. 1984).
Neurochemical and immunohistochemical studies of the hippocampus,
dentate gyrus, and entorhinal cortex suggest the presence of two
separate opiold peptide projection systems in this complex (Chavkin
et al. 1985k Gall, this volume: McGinty, this volume).
To identify the molecular forms and quantify the regional contents
of the dynorphin-A and [Leu5]-enkephalin immunoreactivity, peptide
extracts of microdissected hippocampal regions were resolved by re-
versed phase high-pressure liquid chromatography (HPLC) and
molecular exclusion HPLC (Chavkin et al. 1983b). These studies
demonstrated that the dynorphin-A and [Leu5]enkephalin immuno-
staining corresponded to authentic dynorphin-A(1-17) and
[Leu5]enkephalin. The probable neurotransmitter roles of
[Leu5]enkephalin and dynorphin-A were further supported by our
demonstration of calcium-dependent release of these peptides after
in vitro depolarization of hippocampal tissue (Chavkin et al. 1983a).
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Release of putative transmitters from hippocampal slices was in-
duced by cellular depolarization using 50 mM KCI, veratridine, or
kainic acid added to the super-fusion buffer. The effluents were
assayed using specific radioimmunoassays for [Leu5]enkephalin and
each of the five known prodynorphin derived opioids. Although
transmitter release induced by chemical depolarization may not
precisely mimic endogenous release stimuli, the results of these
experiments show that each of the endogenous dynorphin oploids is
present in the hippocampus and has the potential of being released
by physiological stimuli.
Thus, certain minimal criteria necessary to establish a neuro-
transmitter role of the oploid peptides in the hippocampus have
been satisfied. Anatomical methods have identified the distribution
of the peptides within the hippocampus, and depolarization-induced
release of opioids has been shown. Opioid binding sites are present
in this region as demonstrated by membrane binding and slice auto-
radiography (Herkenham and McLean, this volume). Further char-
acterization of the neurotransmitter role of the opioids in the
hippocampus requires that the actions of opioids be more completely
understood, that the cellular distribution and types of the receptors
mediating those effects be defined, and that endogenous opioid re-
lease be physiologically demonstrated. Significant progress has
been made toward these goals.
OPIOID ACTIONS IN THE CA1 REGION
Numerous groups have studied the electrophysiological effects of
opioids in the CA1 region of the rat and guinea pig hippocampi
(see Henderson (1983), Duggan and North (1984) for review). Most
opioids increase pyramidal cell firing rates and increase the elec-
trical excitability of the CA1 region. The latter effect is most
clearly demonstrated by electrical stimulation of afferent fibers
(Schaffer collaterals) in the stratum radiatum. The effect of opi-
oids under these conditions is to consistently increase the sensitiv-
ity of these cells to electrical stimulation measured by a decrease
in the stimulation intensity required to evoke a response. Another
consistent opioid effect is the generation of secondary responses
which follow the primary population spike (figure 1). Despite these
easily demonstrated effects on excitability, intracellular recordings
have shown that opioids do not change intrinsic membrane proper-
ties of CA1 pyramidal cells (Dingledine 1981; Siggins and
Zieglgänsberger 1981).
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FIGURE 1. CA1 pyramidal cell population responses evoked by
afferent stimulation of Schaffer collaterals
NOTE: The stimuiating electrode was placed in the center of the stratum radi-
atum, and the recording electrode was placed at least 1 mm away in
the CA1 pyramidal cell layer. The figure is marked as follows: (a)
control, (b) 2 mM pentylenetetrazole, and (c) 1 µM normorphine.
Arrows mark the primary population spike, and asterisks mark the
afterpotential. Drugs were added to the superfusion buffer bathing the
tissue and allowed to reach steady state concentration before making
experimental measures (10 minutes). Drug effects were completely
reversible within 10 to 60 minutes. The size and number of after-
potentials are dose dependent.
The mechanism of the opioid effect on CA1 pyramidal ceil excit-
ability has been studied by several groups and is thought to be
largely due to reduction of inhibitory input (e.g., excitation
resulting from disinhibition) as proposed by Zieglgänsberger et al.
(1979). Extracellular recording of CA1 interneurons in vitro sup-
port this hypothesis by showing that opioids directly reduce firing
rates and excitability (Lee et al. 1980). As predicted by the dis-
inhibition hypothesis, DADLE and other opioids applied to the
hippocampal slice were found to directly hyperpolarize intemeurons
by increasing their potassium conductance, consistent with the
effects of delta receptor activation in myenteric neurons (Nicoll
and Madison 1984). The resulting reduction in excitability and
firing rate of the intemeurons could decrease gamma-aminobutyric
acid (GABA) release and reduce inhibitory postsynaptic potential
(IPSP) amplitude recorded in pyramidal ceils.
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Raggenbass et al. (1985) also studied the effects of opioids on
nonpyramidal ceils in the CA1 region of the rat hippocampus.
[D-Ala2,MePhe4,Gly-ol5]enkephalin (DAGO) (a mu-selective agonist)
but not U50,488H (a kappa-selective agonist) suppressed the firing
of these cells. This action was direct, since elevated magnesium
and reduced calcium in the superfusion medium did not Mock the
effects of DAGO. The authors concluded that the mu receptor type
was activated, as the effect was shown to be produced by DAGO
but not U50,488H and was Mocked by naloxone. Presumably, the
inhibitory transmitter affected by opioids is GABA, aithough a
direct neurochemical measure of the effect of [D-Ala2]enkephalin-
amide on endogenous GABA release from hippocampal slices failed
to find any reduction in stimulated release (Fan et al. 1982).
To further test the disinhibition hypothesis of opioid action, it is
necessary to investigate the actions of opioid agonists in relation
to GABA and excitatory amino acid receptor antagonists. if opioids
increase CA1 pyramidal excitability by directly inhibiting GABA re-
lease from interneurons, then GABA antagonists should mimic opioid
effects. This is the case; a variety of GABA receptor antagonists
such as pentylenetetrazole, bicuculine, and picrotoxin produce mul-
tiple population bursts in response to afferent stimulation (Herron
et al. 1988; Hablitz and Langmoen 1986; Ashwood and Wheal 1986).
GABA antagonists reduce the IPSP and increase the excitatory
postsynaptic potential (EPSP), resulting in sufficient depolarization
to unmask N-methyl-D-aspartate (NMDA) receptors (Herron et al.
1986; Hynes and Dingledine 1984; King and Dingiedine 1985). NMOA
receptors are a specific subset of excitatory amino acid receptors
named for their most potent agonist (Watkins and Evans 1981).
During moderate stimulation of synaptic afferents, NMDA receptors
are not activated in the hippocampus. D-2-amino.-5-phosphono-
valerate (D-APV), a selective NMDA receptor antagonist, has no
effect by itself on synaptic responses (Koerner and Cotman 1982;
Collingridge et al. 1983; Ashwood and Wheal 1986). However,
several NMDA receptor antagonists display potent anticonvulsant
activity in a variety of in vivo models of epilepsy (Croucher et al.
1982; Meldrum et al. 1983), and D-APV was shown to completely
block CA1 pyramidal cell afterpotentials produced by pentylene-
tetrazole (Herron et al. 1988).
We compared CA1 pyramidal cell population responses evoked in the
absence and presence of the GABA receptor antagonist pentylene-
tetrazole with responses evoked by the mu-selective opioid receptor
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agonist normorphine (figure 1) (Swearengen and Chavkin 1987). In
both cases, drug application resulted in the appearance of a second
population burst (afterpotential) following the primary population
spike. As predicted, D-APV partially blocked normorphine-induced
afterpotentials in CA1 pyramidal cell population responses (figure
2), but did not affect the opioid-induced increase in sensitivity of
FIGURE 2. Effect of D-APV on stimulus-response characteristics of
normorphine-induced afterpotentials
NOTE: The stimulation and recording protocol was identical to that described
in figure 1. Application of normorphine (10 µM) to the tissue elicited a
single afterpotential as in figure lc. in the absence of normorphine,
the afterpotential was completely absent (open Mangles). The maximum
afterpotential amplitude was dependent on the concentration of normor-
phine in the superfusion buffer (closed triangles). Addition of D-APV
to the superfuslon buffer partially blocked the stimulation-dependent
rise in afterpotential amplitude (squares, 16 µM D-APV circles, 50 µM
D-APV
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the primary population spike to afferent stimulation (data not
shown). Thus, the mechanism of opioid action must include, but
not be limited to, an unmasking of NMDA receptors on the CA1
pyramidal cells.
To further define the types of receptors that mediate opioid action
in the CA1 region, we used a selective receptor inactivation para-
digm (Chavkin et al. 1985a). In that study, we measured the ability
of opioids to increase CA1 pyramidal cell sensitivity to electrical
stimulation after pretreatment of the rat hippocampai slice in vitro
with the irreversible mu-selective antagonist beta-FNA. Beta-FNA-
treated slices were insensitive to the effects of normorphine and
[N-MePhe3,D-Pro4] morphiceptin (PL017). Moreover, the effects of
both dynorphin-A and dynorphin-B were almost completely blocked,
suggesting that these agonists activate mu receptors in CA1. In
contrast, the responses to DADLE and DSLET were not significantly
changed by beta-FNA treatment. Our interpretation of these re-
sults is that both mu and delta opioid receptors are involved in the
specific response to opioids in the CA1 region.
Additional receptor characterization was achieved by Schiid analysis
(Neumaier and Chavkin 1988; Neumaier et al. 1988). As expected
for compounds acting through mu opioid receptors, normorphine,
PLO17, and dynorphin-A(1-17) were found to be highly sensitive to
naloxone antagonism in CA1 (apparent dissociation constants were
between 1 and 3 nM for each) (figure 3) (Neumaier and Chavkin
1986; Neumaier et al. 1986). in contrast, the naloxone sensitivity
of DSLET was significantly lower than that of PLO17 (4.5 nM,
P<0.05, n=8).
These results support the conclusion that opioids in the CA1 region
of the rat hippocampus activate mu and delta but not kappa recep-
tors, and that at moderate concentrations the dynorphin opioids can
activate mu receptors (Chavkin et al. 1985a). Although the popula-
tion of opioid receptors acted on by DSLET is different from that
acted on by normorphine, PLO17, and dynorphin-A, the extracellu-
larly measured response to DSLET is very similar to that found
with mu-selective agonists (figure 4a, b, and c).
In analyzing opioid effects in the CA1 region, it is important to
address the disagreement among the published reports on the
effects of dynorphin-A(1-17). We consistently see excitatory
actions of dynorphin-A in the rat hippocampal slice preparation
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FIGURE 3. A comparison of the apparent dissociation constants of
naloxone at receptors activated by opioid agonists in
the CA1 and dentate regions
NOTE: Schild analysis of naloxone-induced shifts of agonist dose-response
curves yielded apparent dissociation constants (Ki values) for naloxone
at the receptor activated by each agonist used. Each value is the geo-
metric mean plus or minus SEM of two to eight experiments. The mu-
selective agonists normorphine and PL017 were used to determine the
naioxone Ki at mu receptors; these values were not significantly differ-
ent from one another (ranked sum test). The Ki associated with DSLET
was significantly greater than that for PL017 (p<0.05) in both CA1 and
dentate regions. The dynorphin-A(1-17)-related value in CA1 was not
significantly different from that for the mu agonists; however, in the
dentate gyrus, the dynorphin-related value was significantly larger than
that for PL017 in dentate (p<0.01) and dynorphin in CA1 (p<0.05).
(Chavkin et al. 1985a; Neumaier and Chavkin 1986; Neumaier et al.
1986). Others report that dynorphin-A(1-17) is excitatory at low
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FIGURE 4. DSLET causes afterpotentials in CA1 and dentate
regions
NOTE: Extracellular recordings were made from CA1 pyramidal cells (a, b, and
c) and dentate granule cells (d, e, and f) as described in the preceding
text, in both regions, control responses consisted of a stimulus artifact
followed by a fiber potential and a single synaptic population spike (a,
d). DSLET was applied using micropressure pipetes placed very close
to the recording site. The addition of DSLET (1 second, 40 psi, 100
µM) caused a secondary afterpotential in a dose-dependent manner in
both region (b, e). The DSLET effect reversed completely after a
washout of 1 to 3 minutes (c,, data not shown for dentate) and was
completely blocked by naloxone (40 nM) added to the superfusion bath
(f, data not shown for CA1).
concentrations (0.1 nM) but inhibitory at higher concentrations
(Vidal et al. 1984). It is crucial to note that, following in vivo
iontophoretic application of dynorphin-A(1-17), inhibition of extra-
cellularly recorded single-unit firing rate was not reversed by
naloxone (Walker et al. 1982; Henriksen et al. 1982; Moises and
Walker 1995). Des-tyr-dynorphin-A(2-17), a dynorphin analogue
lacking opioid receptor affinity (Chavkin and Goldstein 1981), had
similar inhibitory effects that were insensitive to naloxone (Walker
et al. 1982). Thus, low to moderate concentrations (0.1 nM to 1.0
µM) of dynorphin-A(1-17) can activate mu receptors, producing
typical excitatory effects, while at higher concentrations pyramidal
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cell activity is depressed by a nonspecific and naloxone-insensitive
mechanism.
In summary, current evidence indicates that the excitatory effects
of opioids in the CA1 pyramidal cell region are due to the presence
of functional mu and delta opioid receptors on nonpyramidal cells.
The question of whether single interneurons express both mu and
delta receptors has not yet been resolved. The data suggest that
CA1 intemeurons respond to opioids by increasing potassium con-
ductance; the resulting, hyperpolarization may reduce GABA release
in the region. This reduction in inhibition of the pyramidal cell
leads to activation of NMDA receptors which mediates at least one
component of pyramidal cell excitation.
OPOID ACTlONS IN THE CA3 REGION
In the CA3 region, [Leu5]enkephalin and DADLE consistently
increase pyramidal cell excitability both in vivo (Henriksen et al.
1982; Moises and Walker 1985) and in vitro (Masukawa and Prince
1982; Gruol et al. 1963). In contrast, dynorphin-A(1-17) has
variable effects on CA3 pyramidal cell excitability (Gruol et al.
1963; Chavkin and Bloom 1986; lwama et al. 1986).
Henrisen et al. (1962) studied the effects of iontophoretic and
micropneumatic application of the dynorphins on hippocampal
pyramidal cell firing rates in vivo. The excitatory dynorphin
effects appear to be mediated by an opioid receptor, because the’
nonopioid analogue des-tyr-dynorphin-A(2-17) was inactive, and the
excitatory effects were blocked by systemically or iontophoretically
applied naloxone. In comparison, Bradley and Brookes reported that
the inhibitory responses to iontophoretically applied dynorphin-
A(1-13) in vivo were blocked by naloxone (Bradley and Brookes
1984; Brookes and Bradley 1984). Interpretation of this study is
difficult, however, because the exact region of the hippocampus
(e.g., CA1 , CA3, or dentate) was not identified. In addition, these
findings are not consistent with those of Walker et al. (1982) who
reported that, in the CA3 region, dynorphin-A(1-17) had only
naloxone-insensitive inhibitory effects. In their hands, des-tyr-
dynorphin also reduced the CA3 spontaneous firing rate, but the
observed inhibition was not naloxone reversible.
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The results obtained in vitro have also been controversial. We
have compared the effects of dynorphin-A(1-17) and [Leu5]enkepha-
lin on CA3 pyramidal cell excitability using extracellular field
potential recording methods in the hippocampal slice (Gruol et al.
1963). [Leu5]enkephalin consistently enhanced the pyramidal ceil
responses. However, in different slices, dynorphin-A(1-17) either
increased or decreased pyramidal sensitivity to mossy fiber stimula-
tion. One example of a clear excitatory effect is shown in figure
5: dynorphin-A(1-17)-induced afterpotentials were completely
blocked by 20 nM naloxone. The basis for this inconsistency is not
known, but it may be due to differences in viability among the
slices.
lwama et al. (1966) similarly reported mixed effects of dynorphin-
A(1-17) on guinea pig hippocampal slices. In that study, the
depressions produced by dynorphin-A(-17) were also produced by
very high concentrations (100 µM) of U50,488H and bremazocine
and were not reversed by naloxone (100 µM). The authors suggest
that the inhibitory action may be mediated by kappa receptors.
However, the low potency of kappa agonists and the insensitivity of
the effect to naloxone antagonism indicate that the observed
depression was not likely to have been mediated by an opioid
receptor.
To further investigate the actions of dynorphin-A(1-17) in the CA3
region, we have recorded intracellularly from hippocampal pyramidal
cells in vitro (Gruol et al. 1963). Dynorphin-A(1-17) added to the
superfusion buffer produced variable effects on the spontaneous
activity, burst discharges, and membrane potential. Neither ortho-
dromically evoked synaptic potentials nor resting input resistance
were significantly altered by dynorphin-A(1-17). In this system,
[Leu5]enkephalin reduced IPSPs with no change in membrane poten-
tial or input resistance, in accord with previous studies in CA1
(Masukawa and Prince 1982). The predominant effect we observed
using dynorphin-B(1-13) was a moderately long duration (0.1 to 10.0
seconds) depolarizing response of 5 to 20 mV that was completely
blocked by naloxone (Chavkin and Schwartzkroin, unpublished
observations). No consistent effect of dynorphin-B was seen on the
other components of the spontaneous or synaptically activated re-
sponses including IPSPs evoked by mossy fiber stimulation or the
after hyperpolarization following intrinsic bursts.
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FIGURE 5. Dynorphin-A(1-17) causes after potentials in CA3
NOTE: Guinea pig CA3 pyramidal cells were electrically stimulated In the
mossy fiber tract (150 µA), and their activity was recorded extra-
cellularly in the stratum pyramidale. Control responses showed no
afterpotentials (a). Following application of dynorphln-A(1-17) (1
second, 40 psi, 100 (µM), multiple afterpotentials were generated (b).
These afterpotentials disappeared completely following 1 to 3 minutes of
washout (c) and were completely blocked by 20 nM naloxone (d).
Schild analysis of the shift in dynorphln-A(1-17) dose-response curves
with bath superfusion of naloxone at 10, 20, and 40 nM yielded an
apparent dissociation constant of 4.8 nM (data not shown).
The basis for the different findings reported by different labora-
tories is unclear but may be due to differences in tissue prepara-
tion or method of peptide application. It is also possible that the
potent nonspecific actions of the dynorphin peptides may obscure
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the specific, opioid-receptor-mediated actions under the experimen-
tal conditions used. We expect that the dynorphins have pre-
synaptic disinhibitory effects in CA3 based on the typical inhibitory
actions of opioids seen in other brain regions. However, neither
the receptor types present nor the ionic basis for the opioid
actions in the CA3 region have yet been established.
OPIOID ACTlONS IN THE DENTATE REGION
Since dynorphin and enkephalin peptides are present in the dentate
granule cells and their processes, it is possible that these peptides
are released from dentate granule cell collaterals to modulate
neuron excitability within the dentate gyrus. In addition, the pro-
enkephalin-derived opioids present in the perforant pathway are
likely to be released at terminals in the dentate molecular layer.
Intracellular and extracellular recordings as well as behavioral data
indicate that opioids have effects on the dentate granule cells
(Haas and Ryall 1980; Tielen et al. 1981; Linseman and Corrigall
1982; Collier and Routtenberg 1984). Using rat and guinea pi
hippocampal slices, Tielen et al. (1961) found that [D-Ala2,Met5]en-
kephalin added to the superfusion buffer caused a naloxone-sensi-
tive depression of the evoked response at peptide concentrations
between 0.3 and 1.0 µMI.
We find that extracellular recording in the granule cell layer
following orthodromic perforant path stimulation reveals a
stimulus-response relationship that differs from that found in CA1
or CA3 (figure 6). Whereas the stimulus-response cures always
plateau in CA1 and CA3, a biphasic relationship is often observed
in the dentate region. The biphasic pattern may reflect the re-
cruitment of inhibitory input to granule cells at high stimulus
intensities. Both the inhibition and the excitation have been shown
to be sensitive to opioids (Tielen et al. 1981; Neumaier et al. 1986).
Our findings suggest that the main effect of opioids on the primary
population spike in the dentate gyrus was to transform the
stimulus-response relationship from a biphasic to a sigmoidal shape
without an apparent increase in sensitivity to electrical stimulation
of the primary spike (figure 6). This is different from the opioid-
induced shift to the left of the stimulus-response curves seen in
CA1 and CA3 and may reflect differences in the synaptic circuitry.
An additional naloxone-sensitive effect of opioids in the dentate
gyrus was the dose-dependent induction of afterpotentials (Neumaier
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FIGURE 6. Stimulus-response curves in the hippocampus are altered
by opioids
NOTE: Stimulus-response curves were generated by measuring the amplitude of
the primary spike while varying the intensity of electrical stimulation.
In each region, a control curve was constructed, an opioid was intro-
duced, and then a new stimulus-response curve was measured. In CA1
and CA3, normorphine (5 µM) added by bath superfusion caused a shift
to the left in the stimulus-response relationship with no change in the
maximum response. In the dentate gyrus, dynorphin-A(1-17) added by
pressure micropipette (1 second, 40 psi, 100 µM) did not shift the curve
to the left, but changed the curve from a biphasic to a sigmoidal shape.
and Chavkin 1988; Neumaier et al. 1988). The effect was reversed
1 to 5 minutes after drug application by micropipette; it was also
completely blocked by the addition of naloxone (10 to 100 nM) to
the superfusion buffer (figure 4). We quantified opioid action by
measuring the amplitude of the afterpotential recorded in the
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granule cell layer. Schild analysis of normorphine sensitivity to
naloxone antagonism yielded an apparent dissociation constant of
1.6 nM (0.9 to 2.6, n=4). This value is very close to the apparent
affinity of naloxone for the mu opioid receptor (Lord et al. 1977).
Similarly, the apparent dissociation constant of naloxone derived
from the shift in PL017 (a mu-selective agonist) was 1.0 nM (0.6 to
1.7, n=4). These values agree well with the results from similar
experiments using the same drugs in CA1 (figure 3) and suggest
that normorphine and PL017 act through the mu receptors in the
dentate region of the hippocampus.
Using the extracellular recording paradigm described above, we
measured the effects of dynorphin-A(1-17) following application by
micropipette. Dynorphin-A(1-17) also caused the appearance of an
afterpotential in the dentate granule cell layer response (Neumaier
and Chavkin 1986; Neumaier et al. 1988). The dynorphin effect was
reversed by naloxone but required a higher concentration than that
required to antagonize completely the actions of normorphine
or PL017. The apparent dissociation constant of naloxone in these
experiments was 12.3 nM (8.4 to 18.1, n=8), which was significantly
larger than that associated with PL017 (p<0.01, ranked sum test).
The resistance of dynorphin-A(1-17) effects to naloxone in the den-
tate region suggests that these effects are mediated by kappa re-
ceptors (Neumaier and Chavkin 1986; Neumaier et al. 1986). In
similar experiments (figure 4d, e, and f), we found that DSLET-
induced afterpotentials were inhibited by naloxone with an apparent
dissociation constant of 5.2 nM (n=3). Although this value is lower
than that typically seen with delta receptor activation (Lord et al.
1977), the naloxone sensitivity of DSLET was significantly higher
than that found for PL017 in the same assay. The receptor types
activated by DSLET are not yet known. We can speculate that the
intermediate naloxone sensitivity indicates that DSLET activates
both mu and delta receptors under these assay conditions.
CONCLUSIONS
An image of endogenous opioid action in the hippocampus is emerg-
ing. Disinhibition of the principal cell type is the most consistent
effect of pharmacologically applied opioids in each of the three
major divisions of the hippocampal formation. This was most
clearly demonstrated in the CA1 region, and recent studies have
documented similar actions in CA3 and the dentate gyrus. Addi-
tional experimental details are necessary to define precisely the
110
cell type expressing the opioid receptors, the location of the re-
ceptors on the cell, and the transmitter(s) whose release is con-
trolled by opioid receptor activation. while similarity among the
regions is evident, differences have also been noted in the re-
sponses to opioid application; thus, differences in the synaptic
circuitry are likely.
The analysis of opioid action in the hippocampus continues to re-
quire an understanding of the conditions under which endogenous
opioids are released and the cellular targets of the released opioid.
In addition, we will need to compare the actions of endogenously
released enkephalins and dynorphins with the effects of pharmaco-
logical activation of opioid receptors. Ultimately, this information
will provide a clearer view of the role of endogenous opioids in
controlling the excitability of hippocampal neurons and information
transfer through this brain region.
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Behavioral Significance of
Opioid Peptides in Relation
to Hippocampal Function
Michela Gallagher
INTRODUCTION
The first reference to an action of opiates on learning and memory
can be found in a report published in 1920 (Macht and Mora 1920).
This archival study would seem a fitting background for considering
some behavioral implications of the hippocampal opioid peptides
described in previous chapters. These early investigators reported
that low (subanalgesic) doses of morphine impaired a “memory
habit” in rats tested on a circular maze. This observation echoes
two prominent themes in contemporary behavioral studies on hippo-
campal function. On the one hand, the results from a variety of
research studies point to the role of the hippocampus in memory
(Mishkin 1982; Olton 1983; Zola-Morgan et al. 1988). At the same
time, much evidence indicates that rat hippocampal neurons process
spatial information such as that required in many maze-learning
tasks (O’Keefe and Nadel 1978).
This inquiry will begin by considering the effects of altering opioid
peptide function on learning and memory processes that are associ-
ated with the hippocampus. A second line of inquiry will focus on
the possibility of oploid peptide regulation of afferents to the
hippocampal formation. Primarily, my remarks will address evidence
that septohippocampal choiinergic (acetylcholine (ACh)) function is
under opiold peptide control. Finally, some preliminary evidence
will be discussed indicating that training procedures, which engage
hippocampal function, might be used to monitor opioid peptide
activity in this structure.
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OPlOlD PEPTlDE REGULATlON OF MEMORY FOR SPATIAL
INFORMATlON
Ample evidence is now available indicating that opiate treatments
alter learning and memory across a wide array of tasks and species
(see recent review by Gallagher (1985)). With one notable excep-
tion discussed later in this chapter, the results from this work are
quite uniform. in general, low doses of opiate agonists and pep
tides have detrimental effects, whereas opiate antagonist adminis-
tration, by itself, augments the effects of training on acquisition
and retention of new learning. Drug treatments can produce these
effects when administered either prior to training or during an
interval after the training experience is completed. When exam-
ined, the effects of opiate treatments are found to exhibit stereo-
specificity and to be shared by a series of compounds with either
agonist or antagonist properties.
Quite a few studies in this line of work have used testing proce-
dures that are also sensitive to treatments which affect the hippo-
campal formation. For example, several studies have examined the
effects of opiate antagonists on memory-based performance using
spatial tasks that are sensitive to hippocampal damage. In one
such study, Collier and Routtenberg (1984) tested rats on a radial
arm maze task in which animals were trained to remember the
location of a food reward over a delay period. Either drug or
vehicle injections were given prior to sessions when presentation of
a food reward at one location on the maze was followed 20 minutes
later by a retention test, when animals were again rewarded if they
returned to the same location on the maze. The rewarded location
varied among the eight arms of the maze across test sessions. Ad-
ministration of naloxone was found to facilitate accurate perform-
ance: following drug treatment, animals committed fewer errors
after the delay in returning to the previously rewarded location.
Rats with hippocampal damage fail to perform accurately on this
maze task (Kesner and DiMattia 1984). Interference with normal
hippocampal function produced by intracranial electrical stimulation
likewise impairs performance (Bierley et al. 1983; Collier and
Routtenberg 1984). Indeed, in their study, Collier and Routtenberg
(1984) found that electrical stimulation of the dentate gyrus after
the training trial impaired subsequent retention. In addition, this
effect of hippocampal stimulation was prevented by prior systemic
administration of naloxone. At the time, these investigators
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speculated that the disruptive effects of dentate stimulation on
memory might be due to the release of opioid peptides from dentate
granule cells.
In our laboratory, we have developed a somewhat different version
of the radial arm maze task to examine the effects of opiate
treatments on memory-based performance using spatial information.
Animals are trained to visit each arm of the maze once in a ses-
sion in one spatial environment. The experiment is then conducted
by examining acquisition of criterion performance on the maze in a
series of new spatial environments. In each new environment,
probe trials are conducted to confirm that the accurate perform-
ance which develops over several training trials depends on spatial
cues specifically located around the maze in the new room. In
each new spatial environment, a treatment is given-either drug or
vehicle. Injections are administered after removing the animal from
the maze 5 or 8 hours prior to testing subsequent performance. We
have found highly reliable and robust improvement in acquisition of
criterion performance on this task when opiate antagonists are
given. The data in table 1 are collected from several experiments
and show this effect with systemic administration of several differ-
ent opiate antagonist agents (Fanelli et al. 1985; Gallagher et al.
1983; Gallagher et al. 1985a).
In these studies using rats, opiate antagonists do not disrupt func-
tions that presumably depend, at least in part, on hippocampal cir-
cuitry. Indeed, there is no evidence from this work that activation
of these or other opioid peptides supports or improves the behav-
iors monitored in these experiments; when opiate antagonists are
given, the results uniformly reveal improved performance. Based on
these findings, we might even speculate that activation of hippo-
campal opioid peptides might restrain or diminish the learning/
memory capacities that depend on hippocampal processing; but, of
course, none of these experiments have shown that antagonists act
by modifying opioid peptide activity in the hippocampal formation.
This is especially important to note because, clearly, the behaviors
examined in these studies are not uniquely sensitive to hippocampal
manipulations. Other sites within functionally related neural
systems may serve as targets for the effects of opiate antagonist
treatments. For example, such a target site may be provided by
opioid peptides/binding sites located in the septal region.
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TABLE 1. Rats tested on the radial arm maze in novel spatial
environments
Saline Vehicle Condition Opiate Antagonist Condition
Trials to Errors to Trials to Errors to
N Criterion Criterion Criterion Crieterion
8 5.4 12.0 3.3 * a
1 0 4.9 3.6 * b
1 0 4.8
12.2
5:8
10.6
2 7 12.0
3.5 * a
3.7*c
*Significantly different from vehicle.
aDrug treatment with naloxone (2 mg/kg).
bDrug treatment with diprenorphine (1 mg/kg).
cDrug treatment with naltrexone (1 mg/kg).
SOURCE: Adapted from Gallagher et al. 1983; Gallagher et al. 1985a.
4 . 4 *
5 . 8 *
3 . 7 *
5 . 0 *
OPIOID PEPTlDE REGULATlON OF AFFERENTS TO THE
HIPPOCAMPUS FORMATlON
In a series of investigations dating from the late 1970’s, micro-
injections of agonists, morphine and opioid peptides, into the medial
septal area (MSA) in rats were reported to inhibit ACh activity in
the hippocampus (Botticelli and Wurtman 1982; Moroni et al. 1977;
Moroni et al. 1978; Wood et al. 1979). For example, either mor-
phine or beta-endorphin administration into the medial septum
decreases ACh turnover in the hippocampal formation (Moroni et al.
1977). Inhibition of ACh by opioids is blocked by prior systemic
administration of opiate antagonist, as well as by acute transection
of the fimbria/fornix (Botticelli and Wurtman 1982; Moroni et al.
1977). Such findings led to the proposal that opiate-sensitive
mechanisms in the vicinity of ACh perikarya inhibit septo-
hippocampal ACh neural activity. Endogenous opioid peptides may
also regulate normal septohippocampal ACh function. For example,
systemic administration of naltrexone prevents inhibition of ACh
activity in the hippocampus that can be induced by an episode of
stress (Lai et al. 1988). lt is notable that this effect of opiate
antagonist treatment exhibits some selectivity within the basal
forebrain ACh system. While the effect of stress on inhibition of
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ACh activity in the hippocampus is prevented by naltrexone, the
inhibition of ACh function induced in prefrontal cortex by the same
behavioral manipulation remains unaffected by opiate antagonist
treatment (Lai et al. 1988).
The MSA, which has served as a target site for opiate micro-
injections, contains a relatively sparse innervation by opioid
peptides. Dynorphin-like immunoreactivity is absent in the medial
septal nucleus: scattered fibers are seen in the lateral septum
(Khachaturian et al. 1982). Beta-endorphin innervation of the
septal region appears to be confined to the ventral lateral septal
nucleus in a region that does not encroach on the MSA (Finley et
al. 1981). In a report by Gall and Moore (1984), perikarya exhibit-
ing enkephalin-like immunoreactivity were found in the lateral
septum, predominantly in the intermediate lateral septai nucleus.
Enkephalin-immunoreactive fibers/terminals were observed in two
zones: one located dorsolateral to the enkephalin cell bodies at
rostral levels and midlevels of the septum, and another positioned
along the lateral borders of the medial septal nucleus throughout
its rostral/caudal extent.
The distribution of opioid peptides is interesting to consider
alongside the pattern of opiate binding in the septum. Two zones
of opiate-binding sites are apparent in autoradiograms of the septal
region that correspond rather well with the localization of immuno-
reactive fibers/terminals reported by Gall and Moore (1984). In our
analysis of autoradiograms generated from sections through the
rostral/caudal extent of the region, this correspondence is apparent
at all levels of the septum (unpublished observations). These auto-
radiograms of [3H]naloxone binding show a pattern of distribution
that is also similar to that depicted in a recent report using D-
Ala2-MePhe4-Met(o)5-ol-enkephalin (FK) to selectively label mu
binding sites (McLean et al. 1988). In the present context, the
distribution of opioid fibers/terminals and binding sites in proximity
to the MSA is interesting, especially because this area may overlap
the topography of choline acetyltransferase (ChAT)-immunoreactive
neurons that project to the hippocampal formation. Following
injection of retrograde tracer into the hippocampai formation, cells
that double-labelled for ChAT immunoreactivity are notably absent
along the midline (Amarai and Kurz 1984). Rather, these identified
ACh projection neurons at the level of the septum are positioned
laterally within the medial septai nucleus, and their distribution is
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reported to extend Into the adjacent lateral septum. These ana-
tomical details are consistent with the hypothesis that opiate-
sensitive sites within the septal region are in a position to regulate
septohippocampal ACh function.
Recent work in our laboratory has shown that microinjections of
opiate treatments into the medial septum can alter performance on
learning and memory tasks (Bostock and Gallagher, in press;
Gallagher et al., in press). One testing procedure used in this
work is the radial arm maze task already described. In an experi-
ment in which the same animals were tested in four different spa-
tial environments under vehicle and varying doses of naloxone,
posttraining microinjection into the medial septum appreciably
improved performance (table 2).
TABLE 2. Effects of postraining naloxone administration into the
medial septum on performance in new environments
(n=10)
Treatment Trials to Criterion Errors to Criterion
Vehicle 5.1 ± 0.4 14.2 ± 2.1
5  N a l o x o n eng 5.4 ± 0.4 13.5 ± 1.7
5 0  N a l o x o n eng 4.1 ± 0.4* 0.3 ± 1.8**
500  Na loxoneng 5.0 ± 0.4 9.0 ± 1.3*
*Different from vehicle treatment condition; correlated t test, p<0.05.
**Different from vehicle treatment condition: correlated t test, p<0.01.
NOTE: Values given are means ± SEM.
In related experiments (Bostock et al., in press), memory-based per-
formance on this task was found to be impaired by medial septal
administration of beta-endorphin over a range of doses previously
shown to inhibit hippocampal ACh activity (5 to 500 ng) (table 3).
As shown in table 3, the effects of beta-endorphin microinjections
into this area have no detrimental effect on behavior, however,
once animals have already learned to perform well in a given
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spatial environment. These results suggest that opiate-sensitive
sites located outside the hippocampal trisynaptic circuit alter the
ability to retain new spatial information. However, these effects
may be due, at least in part, to changes in hippocampal function
via regulation of septohippocampal activity.
TABLE 3. Effects of beta-endorphin on maze performance
Treatment
Errors to
Achieve
Criteriona
Errors at
Criterionb
Vehicle 13.9 ± 2.0 1.3±0.17
Beta-endorphin 32.0 ± 6.3* 0.9 ± 0.27
*Significantly different from vehicle, p<0.05.
aThese animals (n=12) received vehicle or peptide (500 ng) on the first 4 days
of testing in a new spatial environment.
bThese animals (n=9) received vehicle or peptide (500 ng) on 4 consecutive
days after reaching criterion in a spatial environment.
NOTE: Values given are means ± SEM.
Although opiate antagonists have proved to be quite effective in
altering behavioral capacities that are associated with hippocampal
function, the hippocampus per se is not necessarily a target for
these effects. In this context, it may be important to note that
other afferents to the hippocampal formation, such as the ascending
noradrenergic system, may also be under opioid peptide control.
Here, in contrast to the interactions described between septo-
hippocampal ACh neurons and opiate-sensitive mechanisms, regula-
tion of the norepinephrine (NE) system may occur at the level of
both the NE cell bodies and the NE terminals (Montel et al. 1974;
Nakamura et al. 1982; Pickel et al. 1979; Williams and North 1964).
Inhibition of the evoked release of NE by opiate agonists has most
recently been reported in hippocampal slices from several species
including rats (Jackisch et al. 1984; Jackisch et al. 1966). Recent
behavioral studies have shown that intact function in the dorsal
noradrenergic pathway is necessary for obtaining the memory-
enhancing effects of opiate antagonists (Fanelli et al. 1965;
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Gallagher et al. 1985b). Thus, removing the NE system from opioid
peptide inhibition at the level of the locus coeruleus (LC) and/or in
terminal fields of the hippocampal formation may also influence
these pharmacological effects.
OPIOID PEPTlDES IN THE HIPPOCAMPAL FORMATION
Turning to the opioid peptides that are localized within the hippo-
campal formation, there is little known about the conditions under
which these opioid peptides are normally activated or the effects
they exert on behavior. One interesting correlation has emerged
recently between the effects of treatments aimed at blocking opioid
peptide activity, including anti-Met-enkephalin antiserum adminis-
tered into the hippocampus, and behavior in two different strains
of mice (Castellano 1961; Van Abeelen and Gerads 1966; Van
Abeelen and Van den Heuvel 1962). The DBA/2 and C57BL/6 mice
exhibit opposing responses to each of the treatments used. For ex-
ample, the DBA/2 mice, like rats, show increased retention after
posttraining administration of naloxone. This same strain shows
increased measures of exploration in a novel environment after
intrahippocampal injection of either naloxone or Met-enkephalin
antiserum. This finding is also reminiscent of the effects of sys-
temic naloxone administration in rats, where increases in stimulus-
directed behavior in a novel complex environment are found
(Arnsten and Segal 1979). In contrast, the C57BL/6 mice yield an
opposite pattern of results on each of these measures. These
studies suggest that hippocampal opioid peptides are activated when
mice explore a novel environment, but there are quite distinctive
effects on behavior in these two genotypes.
Using a somewhat different approach, we have begun to examine
whether exposing animals to training experiences that should en-
gage hippocampal neurons will alter opioid peptide activity in rats.
In this work, we have an additional interest in determining whether
hippocampal inputs such as those arising from noradrenergic and
cholinergic neurons can be shown to regulate opioid peptide activ-
ity. This interest arises from our focus on learning and memory,
as well as from previous work reporting that lesions of the fimbria/
fornix alter levels of hippocampal opioid peptides (Hoffman 1964;
Hoffman and Zamir 1964; Hong and Schmid 1961).
Initially, we used classical conditioning procedures to examine
whether exposing animals to training would alter opioid peptide
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activity within the hippocampus (Meagher et al. 1966). There is
substantial evidence that hippocampal neural activity is engaged
during such associative learning. When classical conditioning
procedures are used, conditioned responses are observed in a large
proportion of pyramidal neurons In the hippocampus of rabbits
(Berger and Thompson 1976). There is also evidence for neural
correlates of associative learning in the dentate gyrus, as well as
in the hippocampus, of rats (Deadwyier et al. 1979; Deiacour 1984;
Rose 1983; Segal 1973; Segai et al. 1972). In our initial experiment,
the animals that served as subjects received unilateral lesions of
the dorsal noradrenergic bundle 3 to 4 weeks prior to the experi-
ment. These rats were sacrificed either 30 minutes or 3 hours
after a conditioning session in which a tone conditioned stimulus
(CS) and footshock unconditioned stimulus (UCS) were either con-
tingently presented (paired groups, 10 trials) or noncontingently
presented (unpaired groups, 10 presentations of each stimulus).
Subsequent radioimmunoassay for dynorphin A(1-8) in the hippo-
campal formation revealed a significant effect of training and of
time of sacrifice but no effect of the NE lesion. Whereas dynor-
phin A(1-8)-like immunoreactivity (dynA(1-8) LI) was comparable
for paired and unpaired groups sacrificed 3 hours after training
(expressed as picomoies per gram of tissue, wet weight, 10.61 ± 0.41
and 9.64 ± 0.61, respectively), levels were significantly higher in
the paired group relative to the unpaired group when rats were
sacrificed 30 minutes after training (14.36 ± 0.61 and 10.36 ± 1.01,
respectively). Radioimmunoassay of Met5-enkephalin LI activity
yielded no significant difference among these same treatment
conditions.
These results indicate that training procedures similar to those that
differentially affect the develorment of conditioned neural activity
in the hippocampai formation may have distinctive effects on the
content of dynA(1-8) LI presumably within the granule ceil/mossy
fiber pathway in the hippocampus. The relatively higher level of
dynA(1-6) LI in animals that received paired CS/UCS presentations
might conceivably reflect lower utilization of opioid peptide relative
to those animals that received shock noncontingently. Although
unilateral NE lesions were not found to have a significant impact
on these results, we are investigating the possible effects of bi-
lateral NE denervation on opioid peptides. This approach may be
particularly important when considering peptides associated with the
granule cell/mossy fiber pathway because the dentate, as compared
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to the hippocampus, receives a significant bilateral NE innervation
(Loy et al. 1960).
Another condition that engages the activity of large populations of
hippocampai neurons is found when rats explore their environments:
hippocampai neurons have place fields that depend on the spatial
location of the animal (O’Keefe and Nadei 1976). In addition,
Sharpe et al. (1965) have found that exposing rats to a new spatial
environment facilitates neural responses evoked in the perforant/
dentate pathway. This neural enhancement grows over several
days’ exposure to a complex spatial environment. The registration
of spatial information in the activity of the hippocampal formation
is particularly interesting because, as previously cited, lesions of
this structure profoundly affect the ability of rats to perform
accurately on spatial tasks.
in another preliminary study, however, we have not found any reli-
able effect on the opioid peptide content of the hippocampai forma-
tion when rats are trained on a spatial learning task. in this
study, Long-Evans rats were trained for 4 days (four trials per day)
to locate a camouflaged escape platform in a Morris water maze.
These place-trained animals and their yoked controls, who spent an
equivalent amount of time swimming in a tank, were sacrificed 15
minutes after completion of their last session along with experi-
mentally naive subjects. Levels of dynA(1-8) LI and Met5-
enkephaiin LI in the hippocampus were not significantly different
for animals across these conditions. This negative finding is
somewhat more interesting when it is considered that hippocampai
choiinergic function was affected in these same subjects. The
contralateral hippocampus was used to measure sodium-dependent
high-affinity choline uptake in these rats. This measure of ACh
function in the hippocampai formation was selectively decreased in
these same animals by place training relative to their yoked con-
trols (Decker et al., in press). Thus, we have not yet found a
functional relationship between a marker for septohippocampai ACh
activity and altered levels of hippocampai Met5-enkephalin LI, in
contrast to the relationship found in previous reports that fimbria/
fornix transections elevate Met5-enkephalin LI in the hippocampus
(Hoffman 1964; Hoffman and Zamir 1964; Hong and Schmid 1961).
Additionally, plasma corticosterone was measured in our rats at the
time of sacrifice. Whereas a training-induced elevation in 11-
hydroxycorticosteroid was observed relative to behaviorally naive
rats, this index of pituitary-adrenal activation was not accompanied
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by altered opioid peptide immunoreactivity in the hippocampai
formation.
CONCLUSION
Although opiate antagonists are found to improve behaviors that
are highly sensitive to hippocampal damage, we have cautioned that
opiate-sensitive sites outside the hippocampus may be involved.
Possible routes for opiate antagonist improvement of learning and
memory include interactions with the basal forebrain choiinergic
and ascending noradrenergic systems, both of which provide affer-
ents to the hippocampai formation.
As research on opioid peptides enters its second decade, we are
just on the threshold of exploring the functional properties of
these neuropeptides in the hippocampai formation. No conclusions
can yet be drawn about their biological significance. At present,
we know almost nothing about the conditions that favor their re-
lease or the physiological responses evoked by endogenous opioid
peptides-ones that might be revealed in the presence of appropri-
ate antagonists. The view expressed here is that currently avail-
able information about natural stimuli that engage hippocampal
neural activity in intact animals may prove a useful and necessary
adjunct to research using in vitro preparations.
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Effects of Mu Opioid Receptor
Activation in Rat Hippocampal
Slice
Menahem Segal
INTRODUCTION
In the hippocampus, the major action of opioid peptides is to
enhance excitability of both pyramidal and granule cells (Corrigall
1983; Henderson 1983; Zieglgänsberger et al. 1979). Although this
fundamental observation is now generally accepted as true, our
knowledge of opioid action even at this simple level of description
is still incomplete. The specific actions of different classes of
opioids in each region of the hippocampus, for example, have not
yet been systematically studied. Most electrophysiological experi-
ments have been conducted in the CA1 region of the dorsal hippo-
campus, where recording is easiest; yet there are, in the adjacent
CA2 region, three times as many mu- and delta-binding sites as in
CA1 (Crain et al. 1986; Herkenham and McLean, this volume).
Similarly, the ventral hippocampus is far richer in opioid peptides
than the dorsal hippocampus.
The opioid-induced excitation of pyramidal and granule cells is
reportedly due to disinhibition resulting from the hyperpolarization
of inhibitory gamma-aminobutyric acid (GABA)-containing inter-
neurons (Nicoll et al. 1980; Zieglgänsberger et al. 1979). The evi-
dence for this relies on occasional recording from interneurons in
hippocampal slices (Nicoll et al. 1980) and is also supported by in
vitro experiments from other brain structures. In the nucleus locus
coeruleus, particularly, it has been shown convincingly that opioids
cause an increase in some types of potassium currents, which act
to decrease neural excitability (Williams et al. 1982). In other sys-
tems, opioid peptides are found to cause other effects, perhaps on
calcium currents (Werz and Macdonald 1982).
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Whether or not disinhibition is the only mechanism that mediates
opiate action on hippocampal pyramidal ceils and dentate gyrus
granule cells is not clear; there is evidence that opioid peptides
may enhance excitatory postsynaptic potentials (EPSPs) directly,
even when inhibitory postsynaptic potentials (IPSPs) are not affect-
ed by these drugs (Dingledine 1981; Gähwiler 1983; Haas and Ryall
1981; Lynch et al. 1981). Furthermore, it is not clear that excita-
tion is the only effect of opiold peptides on hippocampal pyramidal
ceils; there have been several reports of inhibitory actions of some
peptides and opioid analogues on hippocampal activity (Henriksen et
al. 1982; lwama et al. 1986; Moises and Walker 1985). Clearly,
additional work is still needed to sort out the differences among
conflicting reports. The use of selective agonists for mu, delta,
and kappa receptors (Bostock et al. 1984; Brookes and Bradley 1984;
Chavkin et al. 1985; Neumaier and Chavkin 1986; Henderson 1983;
lwama et al. 1986; Tielen et al. 1981; Valentino and Dingledine
1982; Vidal et al. 1984) will certainly facilitate classification of
different response types, although particular caution must be exer-
cised in using ligands in the proper concentration range, especially
when only a relative selectivity has been demonstrated.
Another puzzling observation is the lack of evidence of any opioid
role following activation of the mossy fiber system (the pathway
that connects the dentate gyrus to the hippocampus proper) which
is known to contain dynorphin A. No naloxone-sensitive response
is seen in CA3 neurons following stimulation of this pathway
(Chavkin and Bloom 1986; Moises and Walker 1985; Henriksen et al.,
this volume). Because the mossy fiber system is presumed to con-
tain an excitatory amino acid (EAA) neurotransmitter in addition
to dynorphin A, a potential role of the opioids in the hippocampus
may be in modulating the effects of other transmitters (Segal 1977).
There is already evidence that mu, delta, and kappa agonists can
modulate the release of acetylcholine or norepinephrine from
hippocampal slices (Jackisch et al. 1986). Moreover, in the hippo-
campus, the enzyme acetylcholinesterase, which is responsible for
the rapid breakdown of acetylcholine, is not only colocalized with
opiate receptors but also has peptidase activity of its own. lt
may therefore be involved in the inactivation of opioid peptide
activity in places where acetylcholine and opioids overlap.
Opioid peptides may also modulate EAA-induced neurotoxicity. In-
jection of kainic acid into the hippocampus, the cerebral ventricles,
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or parenterally, produces marked and specific changes in the hippo-
campus involving initial seizure activity followed by neuronal death.
Concurrent with these seizures are marked initial reductions and
later increases in opioid peptide concentrations in the hippocampus
(Kanamatsu et al. 1986, Gall, this volume). Interestingly, region
CA2, the region with the highest concentration of opioid-binding
sites, is also the region most resistant to the toxic effects of
kainic acid. Although it still has to be shown that the intrinsic
opioids play a role in protecting CA2 from the destructive effects
of EAA neurotoxins, this finding is consistent with such an effect.
Most importantly, the functional significance of opioid peptides in
the normal operation of the hippocampus remains elusive. In part,
the problem may be divided according to the two main hippocampal
peptide types. lf dentate gyrus granule cells do indeed release
dynorphin from terminals as a neurotransmitter or cotransmitter,
and if enkephalin is similarly released by the terminals of perforant
path fibers originating in the entorhinal cortex, then correlation of
the physiological activity of these classes of neurons with the ef-
fects on their targets should yield information on the involvement
of these peptides in the hippocampus. To date, however, it has
proved quite difficult to record from identified opioid cells. As a
result, most information concerning opioid involvement in hippo-
campal function has been accumulated by applying agonists and
antagonists to the postsynaptic targets of the mossy fiber and
perforant pathway systems. Some assessment of opioid concentra-
tion in the hippocampus during structured behavioral tests have
also been utilized to analyze opioid actions on learning (Gallagher,
this volume).
The experiments described below address some of the questions
raised here, and the findings are used to propose a mode of action
for and possible function of the opioid peptides acting at mu recep-
tors in the hippocampus. Specifically, the findings address the
possibility of differences in excitability between regions CA1 and
CA2 in response to the application of the mu agonist D-Ala2-
MePhe4-Gly-ol5-enkephalin (DAGO) (Jackisch et al. 1986), differ-
ences in opioid action along the septotemporal axis of the hippo-
campus, the involvement of other neurotransmitters and extrinsic
afferents in the observed effects of opioids in the hippocampus, and
some of the functional implications of activating mu receptors in
the hippocampus.
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METHODS
Experiments were conducted with transverse slices of rat hippo-
campus as described elsewhere (Segal 1986). An intracellular
recording was made with glass micropipettes containing K-acetate,
and an extracellular recording was made with low-resistance (2- to
3-M) micropipettes containing the superfusion medium. Signals
were amplified with an Axoclamp II amplifier and recorded continu-
ously on a chart recorder. Drugs were applied with the microdrop
technique on the slice, near the recording site. Only one cell (or
extracellular recording position) was recorded from a given slice.
DAGO (a gift from Dr. R. Simantov of the Weizmann Institute,
Rehovot, lsrael) was applied at a microdrop concentration of 1 µM;
the final concentration at the receptor site is unknown but is
probably 10 to 100 times smaller than at the microdrop.
REGIONAL EFFECTS OF DAGO
The first series of experiments was conducted in order to compare
reactivity of CA1 and CA2 neurons to topical application of DAGO.
Systematic experiments were done with eight CA1 and seven CA2
neurons. Resting membrane potential (range -65 to -80 mV) and
spike height (80 to 110 mV) were not different between the two
cell groups. The Input resistance of CA2 cells was slightly lower
than that of CA1 cells (range 12 to 60 mohm). CA2 ceils possess a
unique rectifytng property that was not found in CA1 neurons
(Segal, in preparation). Topical application of DAGO to CA1 cells
produced no significant change in the resting properties of the
recorded neuron. The only marked effect, seen by others with mu
agonists in CA1 cells (Bostock et al. 1984), was a reduction in the
two-component slow IPSP evoked in response to stimulation of the
stratum radiatum. Concurrent with this, the initial EPSP evoked by
the same stimulation was enhanced. In general, the EPSP slope
was unchanged, indicating that the reduction in the IPSP size can
account for the changes in EPSPs. Similar responses were detected
in all CA2 cells tested, with no qualitative differences from the
CA1 responses. in four of the seven CA2 cells examined, applica-
tion of DAGO produced a mild (2 to 2.5 mV) hyperpolarization
(figure 1). This response lasted 1 to 2 minutes and recovered,
while the effect of DAGO on the EPSP-IPSP sequence recovered
only 10 to 20 minutes after drug application. It appears that
DAGO may have two independent effects on CA2 cells, only one of
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FIGURE 1. Effects of DAGO on properties of a CA2 neuron
recorded intracellularly
NOTE: (A) Specimen record of membrane potential -65 mV) and responses to
hyperpolarizing current pulses and afferent stimulation before and after
a microdrop application of DAGO. The hyperpolarizing current pulses
are applied every 5 seconds (bottom record current) and alternate with
afferent stimulation. The latter produces a biphasic response consisting
of an EPSP followed by a slow IPSP. DAGO produces a 2-mV slow
hyperpolarization that develops over 15 seconds after drug application.
(B) An illustration of the EPSP-IPBP sequence before (top) and after
(bottom) application of DAGO. Time scale: 10 seconds for A, 100 msec
for B, 5 mV for both. (C) Input-output relations of the size of the
EPBP and IPSP as a function of simulation intensity before (control,
CON) and after (DAGO) application of the drug.
which is shared by CA1 neurons. The pharmacological nature of
the hyperpolarizing response has yet to be determined.
EXTRINSIC MODULATION OF REACTIVITY TO DAGO
Stimulation of the excitatory afferents residing in the stratum radI-
atum can generate a population action potential (population spike)
in the recorded hippocampus. This population spike results from
concurrent activation of many cells in the recorded area. Normal-
ly, a single population spike is generated and is followed by an
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inhibitory period corresponding to the duration of the IPSP. Topi-
cal application of opiates has been shown by several investigators
to produce a larger population spike, and this is commonly followed
by a secondary afterdischarge (Corrigall and Linseman 1980). We
could replicate these responses following application of DAGO
(figure 2). A secondary afterdischarge, not seen normally in our
preparation, amounted to 48 percent of the initial population spike
after application of DAGO (n=12 slices).
FIGURE 2. Effect of prior fornix transection on the efficacy of
DAGO-induced secondary afterpotential (P2)
NOTE: (A) Examples shown are taken from two slices recorded in the same
experiment, of normal and fornix (Fx)-transected rat hippocampi.
Complete, bilateral Fx transection was performed 1 to 2 weeks before
recording. This transection results in nearly total loss of hippocampal
content of acetylcholinesterase. Neither of the two slices produce a
secondary potential under the control condition, and both produce one in
the presence of DAGO, but the ratio of the second to the first (P2/Pl)
is larger In the normal slice. (B) Data from 12 normal slices and 11 Fx-
lesioned slices are averaged. Error bars are standard errors of the
mean.
In one of several types of experiments designed to examine the
modifiability of the response to DAGO, we used fornix-transected
rats. Fornix transection depletes the hippocampus of most of its
cholinergic, serotonergic, and noradrenergic afferents. In addition,
it disrupts the feedback circuit between the hippocampus and the
septal nuclei. lt has also been reported that fornix transection, or
septal lesion, produces a transient rise in concentrations of opioid
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peptides in the hippocampus (Hong and Schmid 1981). In 11 slices
taken from 4 fornix-transected rat hippocampi, we found that
DAGO produced only a small secondary afterdischarge, about 10
percent of the initial population spike amplitude. These results
suggest one of three possibillties: (1) That fornix transection
reduces the ability to evoke an afterdischarge (this is unlikely
since, in these same slices, a tetanic stimulation is capable of
producing an afterdischarge (Segal, unpublished)); (2) that intrinsic
opioid-containing neurons are regulated by extrinsic afferents, and
the absence of these afferents causes increased activity of opioid-
containing neurons, enhanced production of opioid peptides, and
consequent subsensitivity of postsynaptic opiate receptors; and (3)
that DAGO produces at least part of its observed effects by acting
on afferent terminals arriving via the fornix, and in their absence
the afterdischarge is not recorded. Further experiments are needed
to examine these possibilities.
THE NATURE OF THE SYNAPSE ACTlVATED BY DAGO
The enhancement of EPSPs and the blockade of IPSPs result in the
appearance of a secondary afterdischarge. This enhanced excitabil-
ity can also result from activation on the postsynaptic neurons of
additional receptors that are normally masked by the presence of
inhibitors. lt has been suggested that these additional voltage-
dependent responses are mediated by activation of N-methyl-D-
aspartate (NMDA)-like receptors (Collingridge et al. 1983). If that
is the case, one should be able to block the afterdischarge by
application of an NMDA receptor antagonist. Indeed, application of
P-amino phosphorovaleric acid (2-APV) did block the afterdischarge
while having only a small effect on the DAGO-enhanced primary
population spike (figure 3).
The possibility that opioid peptides uncover a voltage-dependent
NMDA-like receptor has fascinating implications; these receptors
are probably involved in plastic properties of the hippocampus,
including its ability to exhibit long-term potentiation (Kelso et al.
1986; Wigstrum and Gustafsson 1983). The effect of DAGO on the
ability of hippocampal neurons to undergo long-term synaptic
changes was examined in a test condition where synaptic input was
associated with postsynaptic depolarization. A similar condition was
considered recently to be an illustration of a Hebbian synapse
(Kelso et al. 1986), that is, an excitatory synapse that, when acti-
vated when the cell was depolarized, demonstrated subsequent
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FIGURE 3. Effects of NMDA antagonist 2-APV on a secondary
population spike evoked in the presence of DAGO
NOTE: On the left are specimen extracellular records taken (top to bottom) be-
fore and after application of DAGO. and after application of 2-APV in
the presence of DAGO. Note the total disappearance of the secondary
population spike in the presence of 2-APV. On the right Is an input-
output curve of the size of the initial population spike under the three
recording conditions (control, DAGO, and DAGO + 2-APV).
enhancement of its excitation. Initially, we stimulated the stratum
radiatum to record a stable intracellular EPSP followed by the
typical IPSP. The cell was then depolarized by passage of DC cur-
rent pulse concurrent with the application of the afferent stimula-
tion. Under these conditions, we were unable to detect subsequent
long-term changes in the magnitude of the EPSPs elicited by
stratum radiatum stimulation. We then applied DAGO (five cells)
and found that subsequent association between depolarizing current
pulses and EPSPs now produced long-term enhancement of the
EPSPs (figure 4). This enabling function of DAGO might provide a
clue to a role of endogenous opioid peptides in the hippocampus;
activation of opioid neurons may enhance local plasticity. This
possibility will be examined in future experiments.
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FIGURE 4. Enabling action of DAGO on potentietion of EPSPs in a
hippocampal neuron
NOTE: (A) Schematic presentation of the stimulatlon paradigm: Top row is
afferent stimulation; bottom row is intracellular current injection; a to e
refer to averaged PSPs depicted in B. Afferent stimulation was applied
once every 5 seconds. (a) Before association of the afferent stimulation
with the depolarizing current pulses: (b) 1 to 5 minutes after a series of
five large depolarizing current pulses, which produce a series of action
potentials, applied simultaneously with the afferent stimulation; (c) 5
minutes after application of DAGO; (d) as in b; and (e) 10 minutes later.
(B) Series of averages of 10 to 20 PSPs recorded in the conditions seen
in A. (C) Individual PSPs on an expanded scale taken before (during
period b) and after (period c) application of DAGO.
DISCUSSION
The present experiments address some puzzles accumulated over the
past few years in the study of opioid peptides in the rat hippo-
campus. The apparent involvement of extrinsic afferents coming
via the fomix-fimbria in the action of DAGO may indicate that, in
order to appreciate the extent of opioid effects, one has to acti-
vate these extrinsic afferents.
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This is difficult to achieve in the artificial situation inherent in
the slice preparation, where the extrinsic afferents are not func-
tional. Hence, the disinhibiiory action of DAGO and the other opi-
oid peptides might reflect one of several cases of presynaptic
action of these peptides on hippocampal circuits. The reduced effi-
cacy of DAGO in the fornix-transected hippocampus is consistent
with the reported effects of opioids on release of acetylcholine and
noradrenaline in the hippocampus. Acetyicholine has several loci of
action in the hippocampus and elsewhere: it causes a decrease in
evoked PSPs, depolarizes postsynaptic cells in a slow manner, pro-
duces a fast activation of interneurons, and causes an increase in
spontaneous PSPs. lt is possible that the opioid peptides modulate
only some of these effects, i.e., those taking place near the pyram-
idal cell layer. lf this is indeed the case, it introduces a measure
of specificity into a neural pathway-the cholinergic septohippo-
campal connection-which is inherently diffuse.
The enabling action of DAGO on activation of an NMDA receptor is
of important functional significance. In previous experiments on a
Hebbian synapse, it was necessary to block inhibition using GABA
antagonists (Kelso et al. 1986). The meaning of such experiments
was not clear because the brain is not known to contain an intrin-
sic GABA-antagonist-like compound. If an opioid-containing neuron
can function to enable an NMDA receptor, then the interpretation
of such experiments is more straightforward. One has to find the
conditions that will activate opiold-containing neurons and demon-
strate that such conditions will also facilitate plasticity in the
hippocampus and then learning by the animal.
SUMMARY
The effects of the mu opioid agonist DAGO were examined in the
hippocampal slice preparation. The effects of the drug on active
and passive properties of neurons in CA1 and CA2 were examined.
Intracellular responses of these neurons to afferent stimulation
were examined before and after DAGO application. As seen with
other mu agonists, DAGO reduced IPSPs and enhanced the duration
of EPSPs but not their rise time. in CA2 cells, DAGO also pro-
duced a transient hyperpolarization. Further experiments examined
the interactions of the opioid peptides with other neurotransmitter
systems in the hippocampus. The effects of DAGO were reduced by
prior fornix transection. Some effects of DAGO on generation of a
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secondary afterdischarge are abolished by an NMDA receptor antag-
onist, 2-APV. The significance of these results to the understand-
ing of functioning of the hippocampal circuit is discussed.
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